1
|
Ozonoff A, Elong Ngono A, Frederick R. Red tape strangles viral surveillance programs. Science 2024; 386:1357. [PMID: 39700277 DOI: 10.1126/science.ads3461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2024]
Affiliation(s)
- Al Ozonoff
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Harvard Medical School, Boston, MA, USA
| | | | | |
Collapse
|
2
|
McNab C, Torreele E, Alakija A, Aluso A, Cárdenas M, Crabb B, Dybul M, Garcia PJ, Gostin LO, Gurría A, Halton J, Kamradt-Scott A, Kazatchkine M, Legido-Quigley H, Liu J, Majumdar S, Mark HE, McCarney R, Miliband D, Mpanju-Shumbusho W, Namchee Lo S, Nordström A, Panjabi R, Saavedra J, Schwalbe N, Stocking BM, Todd E, Wenham C, Johnson Sirleaf E, Clark H. Mpox: Neglect has led to a more dangerous virus now spreading across borders, harming and killing people. Leaders must take action to stop mpox now. PLOS GLOBAL PUBLIC HEALTH 2024; 4:e0003714. [PMID: 39418278 PMCID: PMC11486356 DOI: 10.1371/journal.pgph.0003714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2024]
Affiliation(s)
- Christine McNab
- Independent Consultant, Toronto, Canada
- Former Member of The Independent Panel’s Secretariat, Toronto, Canada
| | - Els Torreele
- Independent Researcher and Advisor, Geneva, Switzerland
| | - Ayoade Alakija
- FIND and Special Envoy to ACT-A and Co-Chair of the ACT-A Principals, Abuja, Nigeria
| | - Aggrey Aluso
- Resilience Action Network Africa, Nairobi, Kenya
| | - Mauricio Cárdenas
- Former Minister of Finance of Colombia and Member of The Independent Panel, Bogota Colombia
| | | | - Mark Dybul
- Diplomat, Physician and Medical Researcher, Member of The Independent Panel, Washington, United States of America
| | | | - Lawrence O. Gostin
- Professor and Chair in Global Health Law and Member of the PGPHC, Washington, United States of America
| | - Angel Gurría
- Organization for Economic Co-operation and Development, Member of the PGPHC, Mexico City, Mexico
| | - Jane Halton
- Coalition for Epidemic Preparedness Innovations (CEPI), Member of the PGPHC, Canberra, Australia
| | - Adam Kamradt-Scott
- Cummings Foundation Professor of One Health Diplomacy, Fletcher School of Law and Diplomacy, Tufts University, Medford, United States of America
| | - Michel Kazatchkine
- The Global Fund to Fight AIDS, Tuberculosis, and Malaria, Member of The Independent Panel, Geneva, Switzerland
| | - Helena Legido-Quigley
- Professor in Health Systems, George Institute for Global Health, Imperial College London, London, United Kingdom
| | - Joanne Liu
- Doctors Without Borders, Member of The Independent Panel, Montreal, Canada
| | - Suman Majumdar
- Chief Health Officer - COVID and Emergencies, Deputy Program Director, Health Security and Pandemic Preparedness, Burnet Institute, Melbourne, Australia
| | | | - Rosemary McCarney
- Former Ambassador and Permanent Representative of Canada to the United Nations, Geneva, Switzerland, Toronto, Canada
| | - David Miliband
- Former Foreign Secretary of the United Kingdom, Member of The Independent Panel, New York, United States of America
| | | | | | - Anders Nordström
- Former Global Health Ambassador for Sweden, Former Head of Secretariat of The Independent Panel, Stockholm, Sweden
| | - Raj Panjabi
- Former White House Senior Director for Global Health Security and Biodefense, Former Advisor to The Independent Panel, Springfield, United States of America
| | - Jorge Saavedra
- AHF Global Public Health Institute, Member of the PGPHC, Miami, United States of America
| | - Nina Schwalbe
- Spark Street Advisors, New York, United States of America
| | - Barbara M. Stocking
- Murray Edwards College, University of Cambridge, Chair of the PGPHC, Cambridge, United Kingdom
| | | | - Clare Wenham
- Associate Professor of Global Health Policy, Department of Health Policy, London School of Economics and Political Science, London, United Kingdom
| | - Ellen Johnson Sirleaf
- Former President of Liberia, Member of The Elders, Co-Chair of The Independent Panel, Monrovia, Liberia
| | - Helen Clark
- Former Prime Minister of New Zealand, Member of The Elders, Co-Chair of The Independent Panel, Auckland, New Zealand
| |
Collapse
|
3
|
Martínez-Pérez GZ, Guerrero CC, Bagnol B, Sarr SC, Mbaye EHM, Diouf O, Touré EHI, Mbengue V, Ndiaye O, Nabil F. Evaluation of a Training Program on Gender Mainstreaming in Health Research Evaluation at the Senegalese National Research Ethics Committee. J Empir Res Hum Res Ethics 2024; 19:103-112. [PMID: 38497221 DOI: 10.1177/15562646241238816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2024]
Abstract
Health research must be of high ethical and scientific quality and consider the needs and experiences of women, men, and nonbinary individuals. National Research Ethics Committees (RECs) are in a strategic position to impede sex- and gender-blind research. In 2020 and 2021, training programs on gender mainstreaming and sex and gender approaches in research evaluation were launched in Senegal. They were evaluated through a mixture of qualitative and quantitative methods. Knowledge acquisition was 16.67%, 8.54%, and 28.42% for the trainees of 2021, 2020, and those who attended the training in both years, respectively. Gender mainstreaming was reported as pertinent in research ethics by 74% of participants. This training is expected to catalyze gender-transformative research ethics in West Africa.
Collapse
Affiliation(s)
| | | | - Brigitte Bagnol
- Department of Anthropology, The University of Witwatersrand, Johannesburg, South Africa
| | | | - El Hadji Mamadou Mbaye
- Social Sciences Department, Institute for Health Research, Epidemiological Surveillance and Training, Dakar, Senegal
| | - Ousmane Diouf
- Ministry of Health and Social Action, Dakar, Senegal
| | | | | | - Oumy Ndiaye
- University of Cheikh Anta Diop-Dakar, Dakar, Senegal
| | - Farah Nabil
- Faculty of Health Sciences, University of Zaragoza, Zaragoza, Senegal
| |
Collapse
|
4
|
Yimer SA, Booij BB, Tobert G, Hebbeler A, Oloo P, Brangel P, L'Azou Jackson M, Jarman R, Craig D, Avumegah MS, Mandi H, Endy T, Wooden S, Clark C, Bernasconi V, Shurtleff A, Kristiansen PA. Rapid diagnostic test: a critical need for outbreak preparedness and response for high priority pathogens. BMJ Glob Health 2024; 9:e014386. [PMID: 38688565 PMCID: PMC11085978 DOI: 10.1136/bmjgh-2023-014386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Accepted: 03/30/2024] [Indexed: 05/02/2024] Open
Abstract
Rapid diagnostic tests (RDTs) are critical for preparedness and response against an outbreak or pandemic and have been highlighted in the 100 Days Mission, a global initiative that aims to prepare the world for the next epidemic/pandemic by driving the development of diagnostics, vaccines and therapeutics within 100 days of recognition of a novel Disease X threat.RDTs play a pivotal role in early case identification, surveillance and case management, and are critical for initiating deployment of vaccine and monoclonal antibodies. Currently available RDTs, however, have limited clinical sensitivity and specificity and inadequate validation. The development, validation and implementation of RDTs require adequate and sustained financing from both public and private sources. While the World Health Assembly recently passed a resolution on diagnostic capacity strengthening that urges individual Member States to commit resources towards this, the resolution is not binding and implementation will likely be impeded by limited financial resources and other competing priorities, particularly in low-income countries. Meanwhile, the diagnostic industry has not sufficiently invested in RDT development for high priority pathogens.Currently, vaccine development projects are getting the largest funding support among medical countermeasures. Yet vaccines are insufficient tools in isolation, and pandemic preparedness will be incomplete without parallel investment in diagnostics and therapeutics.The Pandemic Fund, a global financing mechanism recently established for strengthening pandemic prevention, preparedness and response, may be a future avenue for supporting diagnostic development.In this paper, we discuss why RDTs are critical for preparedness and response. We also discuss RDT investment challenges and reflect on the way forward.
Collapse
Affiliation(s)
| | | | - Gwen Tobert
- Coalition for Epidemic Preparedness Innovations, Oslo, Norway
| | - Andrew Hebbeler
- Coalition for Epidemic Preparedness Innovations, Washington, DC, USA
| | - Paul Oloo
- Coalition for Epidemic Preparedness Innovations, London, UK
| | - Polina Brangel
- Coalition for Epidemic Preparedness Innovations, London, UK
| | | | - Richard Jarman
- Coalition for Epidemic Preparedness Innovations, Washington, DC, USA
| | - Danielle Craig
- Coalition for Epidemic Preparedness Innovations, Washington, DC, USA
| | | | - Henshaw Mandi
- Coalition for Epidemic Preparedness Innovations, Oslo, Norway
| | - Timothy Endy
- Coalition for Epidemic Preparedness Innovations, Washington, DC, USA
| | - Stacey Wooden
- Coalition for Epidemic Preparedness Innovations, Washington, DC, USA
| | - Carolyn Clark
- Coalition for Epidemic Preparedness Innovations, Oslo, Norway
| | | | - Amy Shurtleff
- Coalition for Epidemic Preparedness Innovations, Washington, DC, USA
| | | |
Collapse
|
5
|
Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon JK, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamzé B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BAG. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults. Clin Infect Dis 2024; 78:870-879. [PMID: 37967326 PMCID: PMC11006114 DOI: 10.1093/cid/ciad693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 10/30/2023] [Accepted: 11/10/2023] [Indexed: 11/17/2023] Open
Abstract
BACKGROUND The rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus vaccine indicated for the prevention of Ebola virus disease (EVD) caused by Zaire ebolavirus in individuals 12 months of age and older. METHODS The Partnership for Research on Ebola VACcination (PREVAC) is a multicenter, phase 2, randomized, double-blind, placebo-controlled trial of 3 vaccine strategies in healthy children (ages 1-17) and adults, with projected 5 years of follow-up (NCT02876328). Using validated assays (GP-ELISA and PRNT), we measured antibody responses after 1-dose rVSVΔG-ZEBOV-GP, 2-dose rVSVΔG-ZEBOV-GP (given on Day 0 and Day 56), or placebo. Furthermore, we quantified vaccine virus shedding in a subset of children's saliva using RT-PCR. RESULTS In total, 819 children and 783 adults were randomized to receive rVSVΔG-ZEBOV-GP (1 or 2 doses) or placebo. A single dose of rVSVΔG-ZEBOV-GP increased antibody responses by Day 28 that were sustained through Month 12. A second dose of rVSVΔG-ZEBOV-GP given on Day 56 transiently boosted antibody concentrations. In vaccinated children, GP-ELISA titers were superior to placebo and non-inferior to vaccinated adults. Vaccine virus shedding was observed in 31.7% of children, peaking by Day 7, with no shedding observed after Day 28 post-dose 1 or any time post-dose 2. CONCLUSIONS A single dose of rVSVΔG-ZEBOV-GP induced robust antibody responses in children that was non-inferior to the responses induced in vaccinated adults. Vaccine virus shedding in children was time-limited and only observed after the first dose. Overall, these data support the use of rVSVΔG-ZEBOV-GP for the prevention of EVD in at-risk children. Clinical Trials Registration. The study is registered at ClinicalTrials.gov (NCT02876328), the Pan African Clinical Trials Registry (PACTR201712002760250), and the European Clinical Trials Register (EudraCT number: 2017-001798-18).
Collapse
Affiliation(s)
| | - Ken Liu
- Merck & Co., Inc., Rahway, New Jersey, USA
| | - Edouard Lhomme
- Inserm, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, University of Bordeaux, Bordeaux, France
| | - Julie Blie
- Partnership for Research on Ebola Vaccines in Liberia (PREVAIL), Monrovia, Liberia
| | - John McCullough
- Advanced BioMedical Laboratories (ABML), Cinnaminson, New Jersey, USA
| | | | | | | | | | | | | | | | - Amy Morgan
- Merck & Co., Inc., Rahway, New Jersey, USA
| | | | | | | | - Benjamin Hamzé
- Pôle Recherche Clinique, Institut National de la Santé et de la Recherche Médicale (Inserm), Paris, France
| | - Oumar Guindo
- University Clinical Research Center (UCRC), Bamako, Mali
| | | | - Abdoul H Beavogui
- Centre National de Formation et de Recherche en Santé Rurale (CNFRSR), Maferinyah, Guinea
| | - Bailah Leigh
- College of Medicine & Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone
| | - Mohamed Samai
- College of Medicine & Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone
| | - Pauline Akoo
- Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine (LSHTM), London, United Kingdom
| | - Alimamy Serry-Bangura
- College of Medicine & Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone
| | - Suzanne Fleck
- Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine (LSHTM), London, United Kingdom
| | - Fatou Secka
- Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine (LSHTM), London, United Kingdom
| | - Brett Lowe
- Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine (LSHTM), London, United Kingdom
| | - Deborah Watson-Jones
- Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine (LSHTM), London, United Kingdom
- Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania
| | - Céline Roy
- Inserm, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, University of Bordeaux, Bordeaux, France
- University of Bordeaux, INSERM, MART, UMS 54, F-33000 Bordeaux, France
| | - Lisa E Hensley
- National Bio and Agro-Defense Facility (NBAF), United States Department of Agriculture (USDA), Manhattan, Kansas, USA
| | - Mark Kieh
- Partnership for Research on Ebola Vaccines in Liberia (PREVAIL), Monrovia, Liberia
| | | |
Collapse
|
6
|
Immunization agenda 2030: A global strategy to leave no one behind. Vaccine 2024; 42 Suppl 1:S5-S14. [PMID: 39004466 DOI: 10.1016/j.vaccine.2022.11.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 08/01/2022] [Accepted: 11/17/2022] [Indexed: 07/16/2024]
|
7
|
Riesle-Sbarbaro SA, Wibbelt G, Düx A, Kouakou V, Bokelmann M, Hansen-Kant K, Kirchoff N, Laue M, Kromarek N, Lander A, Vogel U, Wahlbrink A, Wozniak DM, Scott DP, Prescott JB, Schaade L, Couacy-Hymann E, Kurth A. Selective replication and vertical transmission of Ebola virus in experimentally infected Angolan free-tailed bats. Nat Commun 2024; 15:925. [PMID: 38297087 PMCID: PMC10830451 DOI: 10.1038/s41467-024-45231-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 01/16/2024] [Indexed: 02/02/2024] Open
Abstract
The natural reservoir of Ebola virus (EBOV), agent of a zoonosis burdening several African countries, remains unidentified, albeit evidence points towards bats. In contrast, the ecology of the related Marburg virus is much better understood; with experimental infections of bats being instrumental for understanding reservoir-pathogen interactions. Experiments have focused on elucidating reservoir competence, infection kinetics and specifically horizontal transmission, although, vertical transmission plays a key role in many viral enzootic cycles. Herein, we investigate the permissiveness of Angolan free-tailed bats (AFBs), known to harbour Bombali virus, to other filoviruses: Ebola, Marburg, Taï Forest and Reston viruses. We demonstrate that only the bats inoculated with EBOV show high and disseminated viral replication and infectious virus shedding, without clinical disease, while the other filoviruses fail to establish productive infections. Notably, we evidence placental-specific tissue tropism and a unique ability of EBOV to traverse the placenta, infect and persist in foetal tissues of AFBs, which results in distinct genetic signatures of adaptive evolution. These findings not only demonstrate plausible routes of horizontal and vertical transmission in these bats, which are expectant of reservoir hosts, but may also reveal an ancillary transmission mechanism, potentially required for the maintenance of EBOV in small reservoir populations.
Collapse
Affiliation(s)
- S A Riesle-Sbarbaro
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - G Wibbelt
- Leibniz Institute for Zoo and Wildlife Research, Berlin, Germany
| | - A Düx
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
- Helmholtz Institute for One Health, Greifswald, Germany
| | - V Kouakou
- LANADA, Laboratoire National d'Appui au Développement Agricole, Bingerville, Côte d'Ivoire
| | - M Bokelmann
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - K Hansen-Kant
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - N Kirchoff
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - M Laue
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - N Kromarek
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - A Lander
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - U Vogel
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - A Wahlbrink
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - D M Wozniak
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
- Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
| | - D P Scott
- Rocky Mountain Laboratories, National Institutes of Health, Hamilton, MT, USA
| | - J B Prescott
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - L Schaade
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - E Couacy-Hymann
- LANADA, Laboratoire National d'Appui au Développement Agricole, Bingerville, Côte d'Ivoire
- Centre National de Recherches Agronomiques, LIRED, Abidjan, Côte d'Ivoire
| | - A Kurth
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
| |
Collapse
|
8
|
Das U, Fielding D. Higher local Ebola incidence causes lower child vaccination rates. Sci Rep 2024; 14:1382. [PMID: 38228678 PMCID: PMC10791637 DOI: 10.1038/s41598-024-51633-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 01/08/2024] [Indexed: 01/18/2024] Open
Abstract
Ebola is a highly infectious and often fatal zoonotic disease endemic to West and Central Africa. Local outbreaks of the disease are common, but the largest recorded Ebola epidemic originated in Guinea in December 2013, spreading to Liberia, and Sierra Leone in the following year and lasting until April 2016. The epidemic presented a serious challenge to local healthcare systems and foreign aid agencies: it degraded services, caused the loss of healthcare professionals, disrupted the economy, and reduced trust in modern healthcare. This study aims to estimate the extent to which variation in one long-term measure of the quality of local healthcare (the child vaccination rate) is a consequence of local variation in the intensity of the epidemic. Applying a "difference-in-differences" model to household survey data from before and after the epidemic, we show that in 2018-2019, overall rates of vaccination for BCG, DPT, measles, and polio are lower in Guinean and Sierra Leonean districts that had a relatively high incidence of Ebola; statistical analysis indicates that this is a causal effect. The effects of the epidemic on access to healthcare have been local effects, at least in part.
Collapse
Affiliation(s)
- Upasak Das
- Global Development Institute, University of Manchester, Manchester, M13 9PL, UK
| | - David Fielding
- Global Development Institute, University of Manchester, Manchester, M13 9PL, UK.
| |
Collapse
|
9
|
Obeng-Kusi M, Martin J, Abraham I. The economic burden of Ebola virus disease: a review and recommendations for analysis. J Med Econ 2024; 27:309-323. [PMID: 38299454 DOI: 10.1080/13696998.2024.2313358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Accepted: 01/30/2024] [Indexed: 02/02/2024]
Abstract
BACKGROUND Ebola virus disease (EVD) continues to be a major public health threat globally, particularly in the low-and-middle-income countries (LMICs) of Africa. The social and economic burdens of EVD are substantial and have triggered extensive research into prevention and control. We aim to highlight the impact and economic implications, identify research gaps, and offer recommendations for future economic studies pertaining to EVD. METHOD We conducted a comprehensive librarian-led search in PubMed/Medline, Embase, Google Scholar, EconLit and Scopus for economic evaluations of EVD. After study selection and data extraction, findings on the impact and economics of EVD were synthesized using a narrative approach, while identifying gaps, and recommending critical areas for future EVD economic studies. RESULTS The economic evaluations focused on the burden of illness, vaccine cost-effectiveness, willingness-to-pay for a vaccine, EVD funding, and preparedness costs. The estimated economic impact of the 2014 EVD outbreak in Guinea, Liberia, and Sierra Leone across studies ranged from $30 billion to $50 billion. Facility construction and modification emerged as significant cost drivers for preparedness. The EVD vaccine demonstrated cost-effectiveness in a dynamic transmission model; resulting in an incremental cost-effectiveness ratio of about $96 per additional disability adjusted life year averted. Individuals exhibited greater willingness to be vaccinated if it incurred no personal cost, with a minority willing to pay about $1 for the vaccine. CONCLUSIONS The severe impact of EVD puts pressure on governments and the international community for better resource utilization and re-allocation. Several technical and methodological issues related to economic evaluation of EVD remain to be addressed, especially for LMICs. We recommend conducting cost-of-sequelae and cost-of-distribution analyses in addition to adapting existing economic analytical methods to EVD. Characteristics of the affected regions should be considered to provide evidence-based economic plans and economic-evaluation of mitigations that enhance resource allocation for prevention and treatment.
Collapse
Affiliation(s)
- Mavis Obeng-Kusi
- Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA
| | - Jennifer Martin
- Arizona Health Sciences Library, University of Arizona, Tucson, AZ, USA
| | - Ivo Abraham
- Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA
| |
Collapse
|
10
|
Sevilla JP. COVID-19 vaccines should be evaluated from the societal perspective. J Med Econ 2024; 27:1-9. [PMID: 38014424 DOI: 10.1080/13696998.2023.2287935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 11/22/2023] [Indexed: 11/29/2023]
Abstract
The COVID-19 pandemic demonstrates the importance of valuing vaccines from a broad societal perspective (SP), as opposed to a narrower health-payer perspective (HPP). COVID-19's catastrophic global impacts extend not only to its health-related effects, but also to the profound macroeconomic losses caused by lockdowns required for disease control, leading to the worst global economic crisis in a century. COVID-19 vaccination (CV) has been the central policy tool for resolving this economic crisis, and it has been hypothesized that this macroeconomic benefit alone justifies the cost of CV many times over. Yet HPP-based vaccine valuations are wholly insensitive to this enormous benefit, not allowing it to influence the allocation of given health budgets nor the determination of the magnitudes of such budgets, thereby risking inadequate societal spending on CV. HPP allocates given health budgets to maximize only health, giving no weight to macroeconomic outcomes, causing allocative inefficiency by not allowing welfare-improving trade-offs of health for wealth. HPP assumes health budgets are optimal, not scrutinizing whether their scale adequately reflects the macroeconomic benefits of health spending, thereby risking productive inefficiency by foregoing health spending increases such as on CV that could raise both population-level health and wealth. These allocative and productive inefficiencies in turn distort for-profit R&D incentives, risking dynamic inefficiency. And since the socio-economic and health burdens of COVID-19 are disproportionately borne by the worse off, HPP's failure to promote optimal levels of societal investment in CV may disproportionately burden the worse off as well, exacerbating inequality. Vaccine valuations from the societal perspective allow the allocation and determination of health budgets to reflect macroeconomic and distributional values, thereby promoting allocative, productive, and dynamic efficiency, as well as equity. These considerations of efficiency and equity support evaluating CV, and to ensure a level playing field, all vaccines, from a societal perspective.
Collapse
|
11
|
Guttieres D, Diepvens C, Decouttere C, Vandaele N. Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease. Vaccines (Basel) 2023; 12:24. [PMID: 38250837 PMCID: PMC10819028 DOI: 10.3390/vaccines12010024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/13/2023] [Accepted: 12/22/2023] [Indexed: 01/23/2024] Open
Abstract
Health emergencies caused by epidemic-prone pathogens (EPPs) have increased exponentially in recent decades. Although vaccines have proven beneficial, they are unavailable for many pathogens. Furthermore, achieving timely and equitable access to vaccines against EPPs is not trivial. It requires decision-makers to capture numerous interrelated factors across temporal and spatial scales, with significant uncertainties, variability, delays, and feedback loops that give rise to dynamic and unexpected behavior. Therefore, despite progress in filling R&D gaps, the path to licensure and the long-term viability of vaccines against EPPs continues to be unclear. This paper presents a quantitative system dynamics modeling framework to evaluate the long-term sustainability of vaccine supply under different vaccination strategies. Data from both literature and 50 expert interviews are used to model the supply and demand of a prototypical Ebolavirus Zaire (EBOV) vaccine. Specifically, the case study evaluates dynamics associated with proactive vaccination ahead of an outbreak of similar magnitude as the 2018-2020 epidemic in North Kivu, Democratic Republic of the Congo. The scenarios presented demonstrate how uncertainties (e.g., duration of vaccine-induced protection) and design criteria (e.g., priority geographies and groups, target coverage, frequency of boosters) lead to important tradeoffs across policy aims, public health outcomes, and feasibility (e.g., technical, operational, financial). With sufficient context and data, the framework provides a foundation to apply the model to a broad range of additional geographies and priority pathogens. Furthermore, the ability to identify leverage points for long-term preparedness offers directions for further research.
Collapse
Affiliation(s)
- Donovan Guttieres
- Access-to-Medicines Research Centre, Faculty of Economics & Business, KU Leuven, 3000 Leuven, Belgium; (C.D.); (C.D.); (N.V.)
| | | | | | | |
Collapse
|
12
|
Onwujekwe O, Mbachu C, Okeibunor J, Ezema GU, Ejiofor N, Braka F, Thiam A, Koua EL, Chamla D, Gueye AS. What are the research priorities for strengthening public health emergency preparedness and response in Africa? Health Res Policy Syst 2023; 21:107. [PMID: 37872548 PMCID: PMC10594758 DOI: 10.1186/s12961-023-01059-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 10/06/2023] [Indexed: 10/25/2023] Open
Abstract
BACKGROUND Research evidence is needed to strengthen capacities in emergency preparedness and response (EPR). However, the absence of a clear research agenda limits the optimal use of research evidence. This paper reports on the prioritization of research questions and topics that could contribute to evidence-informed strengthening of EPR capacities in the African region. METHODS The priority-setting consisted of desk review and stakeholder consultation workshop. Twenty-nine people participated in the workshop, including representatives from WHO regional office and EPR focal points in Africa, representatives of research institutions, and partners from Science for Africa Foundation, United Nations Children's Fund and Africa Center for Disease Control. Modified Delphi technique was used to systematically arrive at specific and cross-cutting research priorities in the three broad areas of the EPR, which are program Implementation, Clinical and Epidemiology. The research questions/topics were ranked on five-point Likert scale (1 = very low to 5 = very high) based on seven agreed-on criteria. Research priority score was calculated for each question as the mean of the criteria scores. RESULTS A total of 123 research questions comprising, 29 on Epidemiology, 22 on Clinical, 23 on program Implementation, and 49 on cross-cutting issues were ranked. The top ten research priorities were: knowledge and skills of healthcare workers in detecting and responding effectively to disease outbreaks; quality of data (accuracy, timeliness, completeness) for epidemic prone diseases; determinants of vaccine hesitancy; determinants of infection transmission among health care workers during PHE; effective measures for protecting health workers from highly infectious pathogens in PHE; strategies to improve the effectiveness of contact tracing for epidemic prone diseases; effectiveness of current case definitions as screening tools for epidemic and pandemic prone diseases; measures to strengthen national and sub-national laboratory capacity for timely disease confirmation within the Integrated Diseases Surveillance and Response framework; factors affecting prompt data sharing on epidemic-prone diseases; and effective strategies for appropriate community participation in EPR. CONCLUSIONS The collaborative multi-stakeholder workshop produced a starting list of priority research questions and topics for strengthening EPR capacities in Africa. Action needs to be taken to continuously update the research agenda and support member States to contextualize the research priorities and commission research for timely generation and uptake of evidence.
Collapse
Affiliation(s)
- Obinna Onwujekwe
- Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Enugu, 400001, Nigeria
- Department of Health Administration and Management, College of Medicine, University of Nigeria, Enugu, 400001, Nigeria
| | - Chinyere Mbachu
- Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Enugu, 400001, Nigeria.
- Department of Community Medicine, College of Medicine, University of Nigeria, Enugu, 400001, Nigeria.
| | - Joseph Okeibunor
- World Health Organisation Regional Office for Africa (AFRO), Brazzaville, Congo
| | - Godwin Uchenna Ezema
- Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, Enugu, 400001, Nigeria
- Department of Health Administration and Management, College of Medicine, University of Nigeria, Enugu, 400001, Nigeria
- Enugu State Primary Healthcare Development Agency, Enugu, Nigeria
| | - Nonso Ejiofor
- World Health Organisation Regional Office for Africa (AFRO), Brazzaville, Congo
| | - Fiona Braka
- World Health Organisation Regional Office for Africa (AFRO), Brazzaville, Congo
| | - Adama Thiam
- World Health Organisation Regional Office for Africa (AFRO), Brazzaville, Congo
| | - Etien Luc Koua
- World Health Organisation Regional Office for Africa (AFRO), Brazzaville, Congo
| | - Dick Chamla
- World Health Organisation Regional Office for Africa (AFRO), Brazzaville, Congo
| | - Abdou Salam Gueye
- World Health Organisation Regional Office for Africa (AFRO), Brazzaville, Congo
| |
Collapse
|
13
|
Zeng W, Samaha H, Yao M, Ahuka-Mundeke S, Wilkinson T, Jombart T, Baabo D, Lokonga JP, Yuma S, Mobula-Shufelt L. The cost of public health interventions to respond to the 10th Ebola outbreak in the Democratic Republic of the Congo. BMJ Glob Health 2023; 8:e012660. [PMID: 37848269 PMCID: PMC10583089 DOI: 10.1136/bmjgh-2023-012660] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 09/11/2023] [Indexed: 10/19/2023] Open
Abstract
The 10th Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo (DRC) drew substantial attention from the international community, which in turn invested more than US$1 billion in EVD control over two years (2018-2020). This is the first EVD outbreak to take place in a conflict area, which led to a shift in strategy from a pure public health response (PHR) to a multisectoral humanitarian response. A wide range of disease control and mitigation activities were implemented and were outlined in the five budgeted Strategic Response Plans used throughout the 26 months. This study used the budget/expenditure and output indicators for disease control and mitigation interventions compiled by the government of DRC and development and humanitarian partners to estimate unit costs of key Ebola control interventions. Of all the investment in EVD control, 68% was spent on PHR. The remaining 32% covered security, community support interventions for the PHR. The disbursement for the public health pillar was distributed as follows: (1) coordination (18.8%), (2), clinical management of EVD cases (18.4%), (3) surveillance and vaccination (15.9%), (4) infection prevention and control/WASH (13.8%) and (5) risk communication (13.7%). The unit costs of key EVD control interventions were as follows: US$66 182 for maintaining a rapid response team per month, US$4435 for contact tracing and surveillance per identified EVD case, US$1464 for EVD treatment per case, US$59.4 per EVD laboratory test, US$120.7 per vaccinated individual against EVD and US$175.0 for mental health and psychosocial support per beneficiary. The estimated unit costs of key EVD disease control interventions provide crucial information for future infectious disease control planning and budgeting, as well as prioritisation of disease control interventions.
Collapse
Affiliation(s)
- Wu Zeng
- Department of Global Health, Georgetown University, Washington, District of Columbia, USA
| | - Hadia Samaha
- World Bank Group, Washington, District of Columbia, USA
| | - Michel Yao
- World Health Organization, Geneva, Switzerland
| | - Steve Ahuka-Mundeke
- National Institute for Biomedical Research, Kinshasa, Congo (the Democratic Republic of the)
| | | | - Thibaut Jombart
- MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK
| | - Dominique Baabo
- Project Implementation Unit of World Bank Health Projects, Ministry of Public Health, Hygiene and Prevention, Kinshasa, Congo (the Democratic Republic of the)
| | - Jean-Pierre Lokonga
- Project Implementation Unit of World Bank Health Projects, Ministry of Public Health, Hygiene and Prevention, Kinshasa, Congo (the Democratic Republic of the)
| | - Sylvain Yuma
- Ministry of Public Health, Hygiene and Prevention, Kinshasa, Congo (the Democratic Republic of the)
| | | |
Collapse
|
14
|
Markotter W, Mettenleiter TC, Adisasmito WB, Almuhairi S, Barton Behravesh C, Bilivogui P, Bukachi SA, Casas N, Cediel Becerra N, Charron DF, Chaudhary A, Ciacci Zanella JR, Cunningham AA, Dar O, Debnath N, Dungu B, Farag E, Gao GF, Hayman DTS, Khaitsa M, Koopmans MPG, Machalaba C, Mackenzie JS, Morand S, Smolenskiy V, Zhou L. Prevention of zoonotic spillover: From relying on response to reducing the risk at source. PLoS Pathog 2023; 19:e1011504. [PMID: 37796834 PMCID: PMC10553309 DOI: 10.1371/journal.ppat.1011504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023] Open
Affiliation(s)
| | - Wanda Markotter
- Centre for Viral Zoonoses, Department of Medical Virology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
| | - Thomas C. Mettenleiter
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany
| | | | - Salama Almuhairi
- National Emergency Crisis and Disasters Management Authority, Abu Dhabi, United Arab Emirates
| | | | - Pépé Bilivogui
- World Health Organization, Guinea Country Office, Conakry, Guinea
| | - Salome A. Bukachi
- Institute of Anthropology, Gender and African Studies, University of Nairobi, Nairobi, Kenya
| | - Natalia Casas
- National Ministry of Health, Autonomous City of Buenos Aires, Argentina
| | | | - Dominique F. Charron
- Visiting Professor, One Health Institute, University of Guelph, Guelph, Ontario, Canada
| | - Abhishek Chaudhary
- Department of Civil Engineering, Indian Institute of Technology (IIT), Kanpur, India
| | - Janice R. Ciacci Zanella
- Brazilian Agricultural Research Corporation (Embrapa), Embrapa Swine and Poultry, Concórdia/SC, Brazil
| | | | - Osman Dar
- Global Operations Division, United Kingdom Health Security Agency, London, United Kingdom
- Global Health Programme, Chatham House, Royal Institute of International Affairs, London, United Kingdom
| | - Nitish Debnath
- Fleming Fund Country Grant to Bangladesh, DAI Global, Dhaka, Bangladesh
| | - Baptiste Dungu
- Onderstepoort Biological Products SOC (OBP), Afrivet, B M, Pretoria, South Africa
- Faculty of Veterinary Science, University of Kinshasa, Kinshasa, DR Congo
| | - Elmoubasher Farag
- Ministry of Public Health, Health Protection & Communicable Diseases Divison, Doha, Qatar
| | - George F. Gao
- Chinese Center for Disease Control and Prevention, Beijing, P.R. China
| | - David T. S. Hayman
- Molecular Epidemiology and Public Health Laboratory, Massey University, Palmerston North, New Zealand
| | - Margaret Khaitsa
- Mississippi State University, Starkville, Mississippi, United States of America
| | | | | | | | - Serge Morand
- IRL HealthDEEP, CNRS - Kasetsart University - Mahidol University, Bangkok, Thailand
| | - Vyacheslav Smolenskiy
- Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (Rospotrebnadzor), Moscow, Russian Federation
| | - Lei Zhou
- Chinese Center for Disease Control and Prevention, Beijing, P.R. China
| |
Collapse
|
15
|
Tasnim T, Karim KMR. Impact of COVID-19 on Micronutrient Adequacy and Dietary Diversity among Women of Reproductive Age from Selected Households in Bangladesh. Nutrients 2023; 15:3202. [PMID: 37513619 PMCID: PMC10386131 DOI: 10.3390/nu15143202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Revised: 05/30/2023] [Accepted: 06/13/2023] [Indexed: 07/30/2023] Open
Abstract
Women of reproductive age (WRA) are recognized as a nutritionally sensitive demographic that is vulnerable to micronutrient deficiencies. The purpose of this study is to determine the situation and influencing factors of diet diversity and micronutrient adequacy during the pandemic-induced economic lockdown period among women living in a selected area of Bangladesh. Twenty-four-hour dietary recall was used to measure the nutrient intake and also used for constructing the Minimum Dietary Diversity for Women (MDD-W) and nutrient adequacy ratio (NAR). Household food insecurity and coping strategies were also measured. Multivariate logistic regression was carried out to identify the link between potential risk factors and MDD-W. About two-thirds (59.9%) of the study subjects did not meet the MDD-W threshold. The women's total energy and protein consumptions were 1475.1 kcal and 46.3 g, respectively, with the diversified diet group consuming more than the non-diverse diet group. Except for vitamin C, vitamin A, and vitamin D, all micronutrients evaluated in the diversified diet group had significantly higher NAR values than the non-diverse diet group. The mean adequacy ratio (MAR) of the overall reproductive women was 0.468 ± 0.096, and it was significantly associated with MDD-W. Another notable finding is that attainment of minimal diversity was not sufficient to achieve acceptable nutrient adequacy for women, pertaining to their low-quantity intake. In addition to this, household size, women's education, coping strategy, and the MAR were found to be significant determinants of MDD-W in the multivariate logistic regression analysis. The findings of the present study therefore highlight the impending need for interventions that ensure good dietary quality for women even during crisis periods.
Collapse
Affiliation(s)
- Tasmia Tasnim
- Department of Nutrition and Food Engineering, Daffodil International University, Daffodil Smart City, Birulia, Savar, Dhaka 1216, Bangladesh
| | | |
Collapse
|
16
|
Tóth GE, Hume AJ, Suder EL, Zeghbib S, Ábrahám Á, Lanszki Z, Varga Z, Tauber Z, Földes F, Zana B, Scaravelli D, Scicluna MT, Pereswiet-Soltan A, Görföl T, Terregino C, De Benedictis P, Garcia-Dorival I, Alonso C, Jakab F, Mühlberger E, Leopardi S, Kemenesi G. Isolation and genome characterization of Lloviu virus from Italian Schreibers's bats. Sci Rep 2023; 13:11310. [PMID: 37443182 PMCID: PMC10344946 DOI: 10.1038/s41598-023-38364-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 07/06/2023] [Indexed: 07/15/2023] Open
Abstract
Lloviu cuevavirus (LLOV) was the first identified member of Filoviridae family outside the Ebola and Marburgvirus genera. A massive die-off of Schreibers's bats (Miniopterus schreibersii) in the Iberian Peninsula in 2002 led to its initial discovery. Recent studies with recombinant and wild-type LLOV isolates confirmed the zoonotic nature of the virus in vitro. We examined bat samples from Italy for the presence of LLOV in an area outside of the currently known distribution range of the virus. We detected one positive sample from 2020, sequenced the complete coding region of the viral genome and established an infectious isolate of the virus. In addition, we performed the first comprehensive evolutionary analysis of the virus, using the Spanish, Hungarian and the Italian sequences. The most important achievement of this study is the establishment of an additional infectious LLOV isolate from a bat sample using the SuBK12-08 cells, demonstrating that this cell line is highly susceptible to LLOV infection and confirming the previous observation that these bats are effective hosts of the virus in nature. This result further strengthens the role of bats as the natural hosts for zoonotic filoviruses.
Collapse
Affiliation(s)
- Gábor E Tóth
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- Faculty of Sciences, Institute of Biology, University of Pécs, Pécs, Hungary
| | - Adam J Hume
- Department of Virology, Immunology and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
- National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA
- Center for Emerging Infectious Diseases Policy and Research, Boston University, Boston, MA, USA
| | - Ellen L Suder
- Department of Virology, Immunology and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
- National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA
| | - Safia Zeghbib
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Ágota Ábrahám
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- Faculty of Sciences, Institute of Biology, University of Pécs, Pécs, Hungary
| | - Zsófia Lanszki
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- Faculty of Sciences, Institute of Biology, University of Pécs, Pécs, Hungary
| | - Zsaklin Varga
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- Faculty of Sciences, Institute of Biology, University of Pécs, Pécs, Hungary
| | - Zsófia Tauber
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Fanni Földes
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Brigitta Zana
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Dino Scaravelli
- ST.E.R.N.A., Forlì, Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
| | - Maria Teresa Scicluna
- UOC Virologia, Istituto Zooprofilattico Sperimentale del Lazio e della Toscana "M. Aleandri", Roma, Italy
| | - Andrea Pereswiet-Soltan
- Institute of Systematics and Evolution of Animals, Polish Academy of Sciences, Kraków, Poland
| | - Tamás Görföl
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
| | - Calogero Terregino
- OIE Collaborating Centre and National Reference Centre for Infectious Diseases at the Animal-Human Interface, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Paola De Benedictis
- OIE Collaborating Centre and National Reference Centre for Infectious Diseases at the Animal-Human Interface, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Isabel Garcia-Dorival
- INIA-CSIC, Centro Nacional Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Madrid, Spain
| | - Covadonga Alonso
- INIA-CSIC, Centro Nacional Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Madrid, Spain
| | - Ferenc Jakab
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- Faculty of Sciences, Institute of Biology, University of Pécs, Pécs, Hungary
| | - Elke Mühlberger
- Department of Virology, Immunology and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
- National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA
| | - Stefania Leopardi
- OIE Collaborating Centre and National Reference Centre for Infectious Diseases at the Animal-Human Interface, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
| | - Gábor Kemenesi
- National Laboratory of Virology, Szentágothai Research Centre, University of Pécs, Pécs, Hungary.
- Faculty of Sciences, Institute of Biology, University of Pécs, Pécs, Hungary.
| |
Collapse
|
17
|
Lemmens V, Kelchtermans L, Debaveye S, Chiu W, Vercruysse T, Ma J, Thibaut HJ, Neyts J, Sanchez-Felipe L, Dallmeier K. YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge. NPJ Vaccines 2023; 8:99. [PMID: 37433816 PMCID: PMC10336040 DOI: 10.1038/s41541-023-00699-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Accepted: 06/27/2023] [Indexed: 07/13/2023] Open
Abstract
Ebola virus (EBOV) and related filoviruses such as Sudan virus (SUDV) threaten global public health. Effective filovirus vaccines are available only for EBOV, yet restricted to emergency use considering a high reactogenicity and demanding logistics. Here we present YF-EBO, a live YF17D-vectored dual-target vaccine candidate expressing EBOV glycoprotein (GP) as protective antigen. Safety of YF-EBO in mice was further improved over that of parental YF17D vaccine. A single dose of YF-EBO was sufficient to induce high levels of EBOV GP-specific antibodies and cellular immune responses, that protected against lethal infection using EBOV GP-pseudotyped recombinant vesicular stomatitis virus (rVSV-EBOV) in interferon-deficient (Ifnar-/-) mice as surrogate challenge model. Concomitantly induced yellow fever virus (YFV)-specific immunity protected Ifnar-/- mice against intracranial YFV challenge. YF-EBO could thus help to simultaneously combat both EBOV and YFV epidemics. Finally, we demonstrate how to target other highly pathogenic filoviruses such as SUDV at the root of the 2022 outbreak in Uganda.
Collapse
Affiliation(s)
- Viktor Lemmens
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology & Vaccine Discovery, BE-3000, Leuven, Belgium
| | - Lara Kelchtermans
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology & Vaccine Discovery, BE-3000, Leuven, Belgium
| | - Sarah Debaveye
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology & Vaccine Discovery, BE-3000, Leuven, Belgium
| | - Winston Chiu
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology & Vaccine Discovery, BE-3000, Leuven, Belgium
| | - Thomas Vercruysse
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), BE-3000, Leuven, Belgium
- AstriVax, BE-3001, Heverlee, Belgium
| | - Ji Ma
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology & Vaccine Discovery, BE-3000, Leuven, Belgium
| | - Hendrik Jan Thibaut
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), BE-3000, Leuven, Belgium
| | - Johan Neyts
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology & Vaccine Discovery, BE-3000, Leuven, Belgium
- GVN, Global Virus Network, Baltimore, MD, USA
| | - Lorena Sanchez-Felipe
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology & Vaccine Discovery, BE-3000, Leuven, Belgium.
| | - Kai Dallmeier
- KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology & Vaccine Discovery, BE-3000, Leuven, Belgium.
| |
Collapse
|
18
|
Wang H, Zeng W, Kabubei KM, Rasanathan JJK, Kazungu J, Ginindza S, Mtshali S, Salinas LE, McClelland A, Buissonniere M, Lee CT, Chuma J, Veillard J, Matsebula T, Chopra M. Modelling the economic burden of SARS-CoV-2 infection in health care workers in four countries. Nat Commun 2023; 14:2791. [PMID: 37188709 DOI: 10.1038/s41467-023-38477-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 05/03/2023] [Indexed: 05/17/2023] Open
Abstract
Health care workers (HCWs) experienced greater risk of SARS-CoV-2 infection during the COVID-19 pandemic. This study applies a cost-of-illness (COI) approach to model the economic burden associated with SARS-CoV-2 infections among HCWs in five low- and middle-income sites (Kenya, Eswatini, Colombia, KwaZulu-Natal province, and Western Cape province of South Africa) during the first year of the pandemic. We find that not only did HCWs have a higher incidence of COVID-19 than the general population, but in all sites except Colombia, viral transmission from infected HCWs to close contacts resulted in substantial secondary SARS-CoV-2 infection and death. Disruption in health services as a result of HCW illness affected maternal and child deaths dramatically. Total economic losses attributable to SARS-CoV-2 infection among HCWs as a share of total health expenditure ranged from 1.51% in Colombia to 8.38% in Western Cape province, South Africa. This economic burden to society highlights the importance of adequate infection prevention and control measures to minimize the risk of SARS-CoV-2 infection in HCWs.
Collapse
Affiliation(s)
| | - Wu Zeng
- Department of Global Health, Georgetown University, Washington, DC, USA.
| | | | | | - Jacob Kazungu
- Health Economics Research Unit, KEMRI Welcome Trust Research Program, Nairobi, Kenya
| | | | - Sifiso Mtshali
- Public Health Medicine Department, University of KwaZulu-Natal, Durban, South Africa
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Dutuze MF, Byukusenge M, Shyaka A, Christofferson RC. A systematic review to describe patterns of animal and human viral research in Rwanda. Int Health 2023; 15:113-122. [PMID: 35650601 PMCID: PMC9384174 DOI: 10.1093/inthealth/ihac031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 03/22/2022] [Accepted: 05/05/2022] [Indexed: 12/02/2022] Open
Abstract
Rwanda is located in the Central East African region where several viral pathogens with global importance were originally described, including human immunodeficiency virus (HIV), Ebola, Zika, Rift Valley Fever (RVF), dengue and a long list of other neglected tropical viral pathogens. Due to many factors, this region has the potential to become a global hotspot for viral emergence. In Rwanda, viral diseases are underreported and the question is whether this is due to the absence of these viruses or a lack of investigation. Like many developing countries, capabilities in Rwanda need improvement despite research efforts throughout the years. This review describes the status of human and animal virus research in Rwanda and identifies relevant research and operational gaps. A comprehensive search was conducted in PubMed for virus research in Rwanda: 233 primary studies on viruses/viral diseases are indexed with connection to Rwanda. From 1958 to 2020, yearly publications generally increased and HIV/acquired immunodeficiency syndrome is the most studied virus. Compared with human viruses, few studies focus on animal and/or zoonotic viruses. The occurrence of the current severe acute respiratory syndrome coronavirus 2 pandemic shows strengthening warning and surveillance systems is critical to efficient preparedness and response. We recommend investment in human capacity, laboratory facilities and research to inform policy for viral surveillance in Rwanda.
Collapse
Affiliation(s)
- M Fausta Dutuze
- Rwanda Institute for Conservation Agriculture, Gashora, Bugesera, Rwanda
| | - Maurice Byukusenge
- Animal Diagnostic Laboratory, Pennsylvania State University, University Park, PA 16802, USA
| | - Anselme Shyaka
- College of Agriculture and Animal Sciences and Veterinary Medicine, University of Rwanda, Kigali, Rwanda.,Center for One Health, University of Global Health Equity, 23WV + R53, Kigali, Rwanda
| | - Rebecca C Christofferson
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
| |
Collapse
|
20
|
Clemens SAC, Clemens R. The need and challenges for development of vaccines against emerging infectious diseases. J Pediatr (Rio J) 2023; 99 Suppl 1:S37-S45. [PMID: 36495947 PMCID: PMC10066445 DOI: 10.1016/j.jped.2022.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 11/11/2022] [Accepted: 11/12/2022] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVE To identify and describe learnings from past pandemics and to suggest a framework for vaccine development as part of epi/pandemic readiness. SOURCE OF DATA Articles/ reviews/letters on pandemic preparedness/ vaccines published between 2005 and 2022 in PubMed, MEDLINE, MedRxiv, BioRxiv, Research Square, Gates Open Research; who.int, cepi.net, visualcapitalist.com, airfinity.com, ted.com websites; press releases. SUMMARY OF FINDINGS Disease pandemics caused by emerging pathogens impacted the social development, health and wealth of most societies in human history. In an outbreak, the first months determine its course. To block an exponential spread and the development of an epi/ pandemic early, vaccine availability in sufficient quantities is of paramount importance. It is inevitable that new human viruses will emerge. Any future pandemic will come likely from RNA viruses through zoonotic or vector transmission, but we cannot predict when or where "Disease X" will strike. Public health, scientific and societal readiness plans need to include: continuous identification of new viruses in common mammalian reservoir hosts; continuous epidemiological surveillance, including wastewater sampling; establishment of prototype vaccine libraries against various virus families sharing functional and structural properties; testing of various and innovative vaccine platforms including mRNA, vector, nasal or oral vaccines for suitability by virus family; functional clinical trial sites and laboratory networks in various geographies; more efficient phasing of preclinical and clinical activities; global harmonization and streamlining of regulatory requirements including pre-established protocols; and societal preparedness including combating any pandemic of misinformation. CONCLUSIONS "Outbreaks are unavoidable, pandemics are optional".
Collapse
Affiliation(s)
- Sue Ann Costa Clemens
- Department of Pediatrics, Oxford University, Oxford, United Kingdom; Institute for Global Health, University of Siena, Siena, Italy
| | - Ralf Clemens
- International Vaccine Institute (IVI), Seoul, South Korea.
| |
Collapse
|
21
|
Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Gaudig M, Mathieu VO, Brogan AJ. Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study. Vaccine 2023; 41:684-693. [PMID: 36526505 DOI: 10.1016/j.vaccine.2022.11.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 11/16/2022] [Accepted: 11/17/2022] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Nonpharmaceutical interventions (NPI) and ring vaccination (i.e., vaccination that primarily targets contacts and contacts of contacts of Ebola cases) are currently used to reduce the spread of Ebola during outbreaks. Because these measures are typically initiated after an outbreak is declared, they are limited by real-time implementation challenges. Preventive vaccination may provide a complementary option to help protect communities against unpredictable outbreaks. This study aimed to assess the impact of preventive vaccination strategies when implemented in conjunction with NPI and ring vaccination. METHODS A spatial-explicit, individual-based model (IBM) that accounts for heterogeneity of human contact, human movement, and timing of interventions was built to represent Ebola transmission in the Democratic Republic of the Congo. Simulated preventive vaccination strategies targeted healthcare workers (HCW), frontline workers (FW), and the general population (GP) with varying levels of coverage (lower coverage: 30% of HCW/FW, 5% of GP; higher coverage: 60% of HCW/FW, 10% of GP) and efficacy (lower efficacy: 60%; higher efficacy: 90%). RESULTS The IBM estimated that the addition of preventive vaccination for HCW reduced cases, hospitalizations, and deaths by ∼11 % to ∼25 % compared with NPI + ring vaccination alone. Including HCW and FW in the preventive vaccination campaign yielded ∼14 % to ∼38 % improvements in epidemic outcomes. Further including the GP yielded the greatest improvements, with ∼21 % to ∼52 % reductions in epidemic outcomes compared with NPI + ring vaccination alone. In a scenario without ring vaccination, preventive vaccination reduced cases, hospitalizations, and deaths by ∼28 % to ∼59 % compared with NPI alone. In all scenarios, preventive vaccination reduced Ebola transmission particularly during the initial phases of the epidemic, resulting in flatter epidemic curves. CONCLUSIONS The IBM showed that preventive vaccination may reduce Ebola cases, hospitalizations, and deaths, thus safeguarding the healthcare system and providing more time to implement additional interventions during an outbreak.
Collapse
Affiliation(s)
- Donal Bisanzio
- RTI International, 701 13th St NW #750, Washington, DC 20005, USA
| | - Ashley E Davis
- RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC 27709, USA
| | - Sandra E Talbird
- RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC 27709, USA
| | | | - Laurent Metz
- Johnson & Johnson Global Public Health, One Johnson and Johnson Plaza, New Brunswick, NJ 08901, USA
| | - Maren Gaudig
- Johnson & Johnson Global Public Health, One Johnson and Johnson Plaza, New Brunswick, NJ 08901, USA
| | | | - Anita J Brogan
- RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC 27709, USA.
| |
Collapse
|
22
|
Keita M, Talisuna A, Chamla D, Burmen B, Cherif MS, Polonsky JA, Boland S, Barry B, Mesfin S, Traoré FA, Traoré J, Kimenyi JP, Diallo AB, Godjedo TP, Traore T, Delamou A, Ki-Zerbo GA, Dagron S, Keiser O, Gueye AS. Investing in preparedness for rapid detection and control of epidemics: analysis of health system reforms and their effect on 2021 Ebola virus disease epidemic response in Guinea. BMJ Glob Health 2023; 8:bmjgh-2022-010984. [PMID: 36599498 DOI: 10.1136/bmjgh-2022-010984] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Accepted: 12/21/2022] [Indexed: 01/05/2023] Open
Abstract
The 2014-2016 West Africa Ebola Virus Disease (EVD) Epidemic devastated Guinea's health system and constituted a public health emergency of international concern. Following the crisis, Guinea invested in the establishment of basic health system reforms and crucial legal instruments for strengthening national health security in line with the WHO's recommendations for ensuring better preparedness for (and, therefore, a response to) health emergencies. The investments included the scaling up of Integrated Disease Surveillance and Response; Joint External Evaluation of International Health Regulation capacities; National Action Plan for Health Security; Simulation Exercises; One Health platforms; creation of decentralised structures such as regional and prefectural Emergency Operation Centres; Risk assessment and hazard identification; Expanding human resources capacity; Early Warning Alert System and community preparedness. These investments were tested in the subsequent 2021 EVD outbreak and other epidemics. In this case, there was a timely declaration and response to the 2021 EVD epidemic, a lower-case burden and mortality rate, a shorter duration of the epidemic and a significant reduction in the cost of the response. Similarly, there was timely detection, response and containment of other epidemics including Lassa fever and Marburg virus disease. Findings suggest the utility of the preparedness activities for the early detection and efficient containment of outbreaks, which, therefore, underlines the need for all countries at risk of infectious disease epidemics to invest in similar reforms. Doing so promises to be not only cost-effective but also lifesaving.
Collapse
Affiliation(s)
- Mory Keita
- Emergency Preparedness and Response, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo .,Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Ambrose Talisuna
- Emergency Preparedness and Response, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
| | - Dick Chamla
- Emergency Preparedness and Response, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
| | - Barbara Burmen
- Health Security Preparedness, World Health Organization, Geneva, Switzerland
| | - Mahamoud Sama Cherif
- Faculty of Sciences and Health Technics, Gamal Abdel Nasser University of Conakry, Conakry, Guinea
| | - Jonathan A Polonsky
- Geneva Centre of Humanitarian Studies, Faculty of Medicine, University of Geneva, Geneva, Switzerland.,Emergency Response, World Health Organization, Geneva, Switzerland
| | - Samuel Boland
- Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK
| | - Boubacar Barry
- Emergency Response, World Health Organization, Geneva, Switzerland
| | - Samuel Mesfin
- Emergency Response, World Health Organization, Geneva, Switzerland
| | - Fodé Amara Traoré
- National Agency for Health Security, Ministry of Health, Conakry, Guinea
| | - Jean Traoré
- National Agency for Health Security, Ministry of Health, Conakry, Guinea
| | - Jean Paul Kimenyi
- Emergency Preparedness and Response, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
| | - Amadou Bailo Diallo
- Emergency Preparedness and Response, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
| | - Togbemabou Primous Godjedo
- Emergency Preparedness and Response, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
| | - Tieble Traore
- Emergency Preparedness and Response, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
| | - Alexandre Delamou
- African Centre of Excellence for the Prevention and Control of Communicable Diseases, Gamal Abdel Nasser University of Conakry, Conakry, Guinea
| | - Georges Alfred Ki-Zerbo
- Office at the African Union (AU) and Un Economic Commission for Africa (UNECA), World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
| | - Stephanie Dagron
- Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Olivia Keiser
- Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Abdou Salam Gueye
- Emergency Preparedness and Response, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo
| |
Collapse
|
23
|
Picchioni F, Goulao LF, Roberfroid D. The impact of COVID-19 on diet quality, food security and nutrition in low and middle income countries: A systematic review of the evidence. Clin Nutr 2022; 41:2955-2964. [PMID: 34535329 PMCID: PMC8390094 DOI: 10.1016/j.clnu.2021.08.015] [Citation(s) in RCA: 88] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 07/22/2021] [Accepted: 08/18/2021] [Indexed: 01/27/2023]
Abstract
BACKGROUND & AIMS The current global pandemic of Coronavirus (COVID-19), and measures adopted to reduce its spread, threaten the nutritional status of populations in Low- and middle-income countries (LMICs). Documenting how the COVID-19 affects diets, nutrition and food security can help generating evidence-informed recommendations for mitigating interventions and policies. METHODS We carried out a systematic literature review. A structured search strategy was applied in MEDLINE (Pubmed®), EMBASE®, Scopus® and Web of Science®. Grey literature was retrieved by screening a pre-set list of institutions involved in monitoring the impact of the COVID-19 pandemic on nutrition and food security. The first search was done on 20th August 2020, and updated in mid-November 2020 and mid-January 2021. All research steps were described as recommended in the PRISMA statement. RESULTS Out of the 2085 references identified, thirty-five primary studies were included. In spite of their heterogeneity, studies converge to demonstrate a detrimental effect of COVID-19 pandemic and associated containment measures on diet quality and food insecurity. One of the major direct effects of COVID-19 on food and nutrition outcomes has been through its impact on employment, income generating activities and associated purchasing power. Other channels of impact, such as physical access, availability and affordability of food provided a heterogeneous picture and were assessed via binary and often simplistic questions. The impacts of COVID-19 on food systems and diets manifested with various intensity degrees, duration and in different forms. Factors contributing to these variations between and within countries were: 1) timing, duration and stringency of national COVID-19 restriction measures and policies to mitigate their adverse impacts; 2) context specific food value chain responses to domestic and international containment measures; 3) differentiated impacts of restriction measures on different groups, along lines of gender, age, socio-economic status and employment conditions. Shorter value chains and traditional smallholder farms were somewhat more resilient in the face of COVID-19 pandemic. Additionally, the impact of the pandemic has been particularly adverse on women, individuals with a low socio-economic status, informal workers and young adults that relied on daily wages. Finally, there were heterogeneous government responses to curb the virus and to mitigate the damaging effects of the pandemic. It has been demonstrated that existing and well-functioning social protection programmes and public distribution of food can buffer the adverse effects on food insecurity. But social safety nets cannot be effective on their own and there is a need for broader food systems interventions and investments to support sustainable and inclusive food systems to holistically achieve food and nutrition security. CONCLUSION The current economic and heath crisis impacted diet quality and food security. This raises concerns about long term impacts on access to and affordability of nutrient-rich, healthy diets and their health implications. Women and individuals with a low socio-economic are likely to be the most at risk of food insecurity. Social safety nets can be effective to protect them and must be urgently implemented. We advocate for improved data collection to identify vulnerable groups and measure how interventions are successful in protecting them.
Collapse
Affiliation(s)
- Fiorella Picchioni
- Natural Resources Institute, University of Greenwich, Central Avenue, Chatham Maritime, Kent, ME4 4TB, UK.
| | - Luis F Goulao
- LEAF (Linking Landscape Environment Agriculture and Food) Research Centre, Instituto Superior de Agronomia, Universidade de Lisboa, Tapada da Ajuda, 1349-017, Lisbon, Portugal
| | - Dominique Roberfroid
- Ghent University, Faculty of Bioscience Engineering, Department of Food Technology, Safety and Health, Belgium; University of Namur, Faculty of Medicine, Department of Medicine, Belgium
| |
Collapse
|
24
|
Anupriya, Bansal P, Graham DJ. Modelling the propagation of infectious disease via transportation networks. Sci Rep 2022; 12:20572. [PMID: 36446795 PMCID: PMC9707165 DOI: 10.1038/s41598-022-24866-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Accepted: 11/22/2022] [Indexed: 11/30/2022] Open
Abstract
The dynamics of human mobility have been known to play a critical role in the spread of infectious diseases like COVID-19. In this paper, we present a simple compact way to model the transmission of infectious disease through transportation networks using widely available aggregate mobility data in the form of a zone-level origin-destination (OD) travel flow matrix. A key feature of our model is that it not only captures the propagation of infection via direct connections between zones (first-order effects) as in most existing studies but also transmission effects that are due to subsequent interactions in the remainder of the system (higher-order effects). We demonstrate the importance of capturing higher-order effects in a simulation study. We then apply our model to study the first wave of COVID-19 infections in (i) Italy, and, (ii) the New York Tri-State area. We use daily data on mobility between Italian provinces (province-level OD data) and between Tri-State Area counties (county-level OD data), and daily reported caseloads at the same geographical levels. Our empirical results indicate substantial predictive power, particularly during the early stages of the outbreak. Our model forecasts at least 85% of the spatial variation in observed weekly COVID-19 cases. Most importantly, our model delivers crucial metrics to identify target areas for intervention.
Collapse
Affiliation(s)
- Anupriya
- grid.7445.20000 0001 2113 8111Transport Strategy Centre, Department of Civil and Environmental Engineering, Imperial College London, London, SW7 2AZ UK
| | - Prateek Bansal
- grid.4280.e0000 0001 2180 6431Department of Civil and Environmental Engineering, National University of Singapore, Queenstown, 119077 Singapore
| | - Daniel J. Graham
- grid.7445.20000 0001 2113 8111Transport Strategy Centre, Department of Civil and Environmental Engineering, Imperial College London, London, SW7 2AZ UK
| |
Collapse
|
25
|
Irawan B, Yulia R. Emerging challenges to prisoners vaccination of covid-19: Historical, legal and humanitarian view. J Public Health Res 2022; 11:22799036221115769. [PMID: 36310829 PMCID: PMC9597029 DOI: 10.1177/22799036221115769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Accepted: 07/09/2022] [Indexed: 11/06/2022] Open
Abstract
This research aims to present a legal history of the prisoners’ treatment in
global crises along with presenting an overview of prisoners’ treatment during
Covid-19 in view of International Humanitarian Laws. Using the formative
research method with a conceptual approach and statute approach, data was
gathered from various legal documents related to prisoners’ health laws linked
to legal purpose theories. This study further explains the need to treat old age
prisoners on a priority basis and to what extent international health
organizations are making efforts to establish criteria to vaccinate this
societal segment. The international regulatory framework was deeply analyzed to
draw conclusions and recommendations along with WHO efforts. It was revealed
that there exist adequate laws regarding priority health treatment of the
prisoners in crises times but existed an enormous need to highlight and address
the sensitive humanitarian issue. Additionally, WHO and other international
organizations have also revised the international laws during Covid-19 to treat
the prisoners. However, there is an immense need to devise explicit regulations
regarding the accessibility of the vaccine to all the groups of society,
including prisoners. The provision of a detailed overview of international laws
and treaties regarding prisoners’ priority health treatment is a major advance
of this research. Further recommendations for the developed and developing
nations and future research directions are suggested.
Collapse
Affiliation(s)
| | - Rena Yulia
- Rena Yulia, Sultan Ageng Tirtayasa
University, Jl. Raya Palka No. Km 3, Panancangan, Kec. Cipocok Jaya, Kabupaten
Serang, Banten 42124, Indonesia.
| |
Collapse
|
26
|
Potluri R, Kumar A, Oriol-Mathieu V, Van Effelterre T, Metz L, Bhandari H. Model-based evaluation of the impact of prophylactic vaccination applied to Ebola epidemics in Sierra Leone and Democratic Republic of Congo. BMC Infect Dis 2022; 22:769. [PMID: 36192683 PMCID: PMC9529325 DOI: 10.1186/s12879-022-07723-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 09/11/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Protection by preventive Ebola vaccines has been demonstrated in clinical trials, but a complete picture of real-world effectiveness is lacking. Our previous study modeling the impact of preventively vaccinating healthcare workers (HCW) alone or with a proportion of the general population (GP) estimated significant reductions in incidence and mortality. The model assumed 100% vaccine efficacy, which is unlikely in the real world. We enhanced this model to account for lower vaccine efficacy and to factor in reduced infectiousness and lower case fatality rate in vaccinated individuals with breakthrough infections. METHODS The previous model was enhanced to still permit a risk, although lower, for vaccinated individuals to become infected. The enhanced model, calibrated with data from epidemics in Sierra Leone (SL) and North Kivu, Democratic Republic of the Congo, helped evaluate the impact of preventive Ebola vaccination in different scenarios based on different vaccine efficacy rates (90% and 30% reductions in infection risk in the base and conservative scenarios, respectively; additionally, both scenarios with 50% reductions in infectiousness and mortality) and vaccination coverage among HCWs (30%, 90%) and GP (0%, 5%, and 10%). RESULTS The base scenario estimated that, depending upon the proportions of vaccinated HCWs and GP, 33-85% of cases and 34-87% of deaths during the 2014 SL epidemic and 42-89% of cases and 41-89% of deaths during the 2018 North Kivu epidemic would be averted versus no vaccination. Corresponding estimates for the conservative scenario were: 23-74% of cases and 23-77% of deaths averted during the SL epidemic and 31-80% of both cases and deaths averted during the North Kivu epidemic. CONCLUSIONS Preventive vaccination targeting HCW alone or with GP may significantly reduce the size and mortality of an EVD outbreak, even with modest efficacy and coverage. Vaccines may also confer additional benefits through reduced infectiousness and mortality in breakthrough cases.
Collapse
Affiliation(s)
- Ravi Potluri
- SmartAnalyst Inc., 300 Vesey Street, 10th Floor, New York, NY, 10282, USA.
| | - Amit Kumar
- SmartAnalyst India Pvt. Ltd., Gurugram, India
| | | | | | - Laurent Metz
- Johnson & Johnson Global Public Health, New Brunswick, NJ, USA
| | | |
Collapse
|
27
|
Daum T, Biesalski HK, Blaschke N, Bosch C, Güttler D, Heni J, Kariuki J, Katusiime R, Seidel A, Senon Z, Woode G, Birner R. Nutrition-sensitive lockdowns: conceptual framework and empirical insights from Africa during COVID-19. DEVELOPMENT POLICY REVIEW : THE JOURNAL OF THE OVERSEAS DEVELOPMENT INSTITUTE 2022; 41:e12666. [PMID: 36245567 PMCID: PMC9538056 DOI: 10.1111/dpr.12666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 07/14/2022] [Accepted: 08/28/2022] [Indexed: 06/16/2023]
Abstract
Motivation Countries facing challenges of nutrition security confront a trade-off when dealing with pandemics such as COVID-19. Implementing lockdown measures, widely used worldwide, can help "flatten the curve" (of disease), but such measures may worsen nutrition security. Purpose We aim to identify and justify nutrition-sensitive lockdown measures to reduce trade-offs with nutrition security. Methods and approach We propose a conceptual framework which distinguishes eight lockdown measures and six pathways to nutrition security. To demonstrate the relevance of the pathways, we reviewed emerging literature on COVID-19 and nutrition security. We analysed the content of 1,188 newspaper articles on lockdown effects in five African countries - Benin, Ghana, Kenya, Uganda and Zambia. Findings Some lockdown measures, such as closing workplaces and restricting movement, potentially worsen nutrition far more than others - banning events and public gatherings have far lesser impacts on nutrition. This can be seen from the framework, literature, and is supported by the analysis of newspaper reports in the five countries. Policy implications It is better when possible to test and trace disease than to lockdown. But when lockdowns are needed, then first recourse should be to measures that have few nutritional consequences, such as banning public events. When more drastic measures are necessary, look to mitigate nutritional harm by, for example, exempting farm labour from restrictions on movement, by replacing school meals with take-home rations, and, above all, providing income support to households most affected and most vulnerable.
Collapse
Affiliation(s)
- Thomas Daum
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | | | - Nikola Blaschke
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | - Christine Bosch
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | - Denise Güttler
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | - Jakob Heni
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | - Juliet Kariuki
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | - Roseline Katusiime
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | - Anna Seidel
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | - Zinsou‐Narcisse Senon
- Regional Agency of Agricultural Development‐PlateauMinistry of Agriculture, Livestock and FisheryRepublic of Benin
| | - George Woode
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| | - Regina Birner
- Institute of Agricultural Sciences in the Tropics (Hans‐Ruthenberg‐Institute)University of HohenheimGermany
| |
Collapse
|
28
|
Kelly JD, Van Ryn C, Badio M, Fayiah T, Johnson K, Gayedyu-Dennis D, Weiser SD, Porco TC, Martin JN, Sneller MC, Rutherford GW, Reilly C, Fallah MP, Moses JS. Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study. THE LANCET. INFECTIOUS DISEASES 2022; 22:1163-1171. [PMID: 35588755 PMCID: PMC9329265 DOI: 10.1016/s1473-3099(22)00127-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 12/30/2021] [Accepted: 01/31/2022] [Indexed: 02/05/2023]
Abstract
BACKGROUND Whether or not individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease develop clinical sequelae is unknown. We assessed current symptoms and physical examination findings among individuals with pauci-symptomatic or asymptomatic infection and unrecognised Ebola virus disease compared with Ebola virus disease survivors and uninfected contacts. METHODS Between June 17, 2015, and June 30, 2017, we studied a cohort of Ebola virus disease survivors and their contacts in Liberia. Surveys, current symptoms and physical examination findings, and serology were used to characterise disease status of reported Ebola virus disease, unrecognised Ebola virus disease, pauci-symptomatic or asymptomatic Ebola virus infection, or no infection. We pre-specified findings known to be differentially prevalent among Ebola virus disease survivors versus their contacts (urinary frequency, headache, fatigue, muscle pain, memory loss, joint pain, neurological findings, chest findings, muscle findings, joint findings, abdominal findings, and uveitis). We estimated the prevalence and incidence of selected clinical findings by disease status. FINDINGS Our analytical cohort included 991 reported Ebola virus disease survivors and 2688 close contacts. The median time from acute Ebola virus disease onset to baseline was 317 days (IQR 271-366). Of 222 seropositive contacts, 115 had pauci-symptomatic or asymptomatic Ebola virus infection and 107 had unrecognised Ebola virus disease. At baseline, prevalent findings of joint pain, memory loss, muscle pain, and fatigue were lowest among those with pauci-symptomatic or asymptomatic infection or no infection, higher among contacts with unrecognised Ebola virus disease, and highest in reported survivors of Ebola virus disease. Joint pain was the most prevalent finding, and was reported in 434 (18%) of 2466 individuals with no infection, 14 (12%) of 115 with pauci-symptomatic or asymptomatic infection, 31 (29%) of 107 with unrecognised Ebola virus disease, and 476 (48%) of 991 with reported Ebola virus disease. In adjusted analyses, this pattern remained for joint pain and memory loss. Survivors had an increased odds of joint pain compared with unrecognised Ebola virus disease contacts (adjusted odds ratio [OR] 2·13, 95% CI 1·34-3·39); unrecognised Ebola virus disease contacts had an increased odds of joint pain compared with those with pauci-symptomatic or asymptomatic infection and uninfected contacts (adjusted OR 1·89, 95% CI 1·21-2·97). The adjusted odds of memory loss was more than four-times higher among survivors than among unrecognised Ebola virus disease contacts (adjusted OR 4·47, 95% CI 2·41-8·30) and two-times higher among unrecognised Ebola virus disease contacts than in those with pauci-symptomatic or asymptomatic infection and uninfected contacts (adjusted OR 2·05, 95% CI 1·10-3·84). By 12 months, prevalent findings had decreased in the three infected groups. INTERPRETATION Our findings provide evidence of post-Ebola virus disease clinical sequelae among contacts with unrecognised Ebola virus disease but not in people with pauci-symptomatic or asymptomatic Ebola virus infection. FUNDING National Cancer Institute and National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Collapse
Affiliation(s)
- J Daniel Kelly
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA; Institute for Global Health Sciences, University of California, San Francisco, CA, USA; F I Proctor Foundation, University of California, San Francisco, CA, USA; Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia.
| | - Collin Van Ryn
- Division of Biostatistics, University of Minnesota, Minneapolis, MN, USA
| | - Moses Badio
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA; Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia
| | - Tamba Fayiah
- Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia
| | - Kumblytee Johnson
- Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia
| | - Dehkontee Gayedyu-Dennis
- Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia
| | - Sheri D Weiser
- Division of HIV, Infectious Disease, and Global Medicine, University of California, San Francisco, CA, USA
| | - Travis C Porco
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA; F I Proctor Foundation, University of California, San Francisco, CA, USA
| | - Jeffery N Martin
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
| | - Michael C Sneller
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - George W Rutherford
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA; Institute for Global Health Sciences, University of California, San Francisco, CA, USA
| | - Cavan Reilly
- Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia; Division of Biostatistics, University of Minnesota, Minneapolis, MN, USA
| | - Mosoka P Fallah
- Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia; A M Dogliotti College of Medicine, University of Liberia, Monrovia, Liberia
| | - J Soka Moses
- Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, Liberia
| |
Collapse
|
29
|
Aasim, Sharma R, Patil CR, Kumar A, Sharma K. Identification of vaccine candidate against Omicron variant of SARS-CoV-2 using immunoinformatic approaches. In Silico Pharmacol 2022; 10:12. [PMID: 35898574 PMCID: PMC9315333 DOI: 10.1007/s40203-022-00128-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Accepted: 06/24/2022] [Indexed: 12/20/2022] Open
Abstract
Despite the availability of COVID-19 vaccines, additional more potent vaccines are still required against the emerging variations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the present investigation, we have identified a promising vaccine candidate against the Omicron (B.1.1.529) using immunoinformatics approaches. Various available tools like, the Immune Epitope Database server resource, and NetCTL-1.2, have been used for the identification of the promising T-cell and B-cell epitopes. The molecular docking was performed to check the interaction of TLR-3 receptors and validated 3D model of vaccine candidate. The codon optimization was done followed by cloning using SnapGene. Finally, In-silico immune simulation profile was also checked. The identified T-cell and B-cell epitopes have been selected based on their antigenicity (VaxiJen v2.0) and, allergenicity (AllerTOP v2.0). The identified epitopes with antigenic and non-allergenic properties were fused with the specific peptide linkers. In addition, the 3D model was constructed by the PHYRE2 server and validated using ProSA-web. The validated 3D model was further docked with the Toll-like receptor 3 (TLR3) and showed good interaction with the amino acids which indicate a promising vaccine candidate against the Omicron variant of SARS-CoV-2. Finally, the codon optimization, In-silico cloning and immune simulation profile was found to be satisfactory. Overall, the designed vaccine candidate has a potential against variant of SARS-Cov-2. However, further experimental studies are required to confirm.
Collapse
Affiliation(s)
- Aasim
- Department of Pharmaceutical Biotechnology, Delhi Pharmaceutical Science, and Research University, New Delhi, 110017 India
| | - Ruchika Sharma
- Centre for Precision Medicine and Pharmacy, Delhi Pharmaceutical Science, and Research University, New Delhi, 110017 India
| | - C R Patil
- Department of Pharmacology, Delhi Pharmaceutical Science, and Research University, New Delhi, 110017 India
| | - Anoop Kumar
- Department of Pharmacology, Delhi Pharmaceutical Science, and Research University, New Delhi, 110017 India
| | - Kalicharan Sharma
- Department of Medicinal Chemistry, Delhi Pharmaceutical Science, and Research University, New Delhi, 110017 India
| |
Collapse
|
30
|
Adejoh SO, Kuznetsova I, Dhesi S. Internally displaced people in Lagos: environmental health conditions and access to healthcare in the context of COVID-19. CRITICAL PUBLIC HEALTH 2022. [DOI: 10.1080/09581596.2022.2096427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- Samuel Ojima Adejoh
- Department of Social Work, Faculty of Social Sciences, The University of Lagos, Lagos, Nigeria
| | - Irina Kuznetsova
- School of Geography, Earth and Environmental Sciences, The University of Birmingham, Birmingham, UK
| | - Surindar Dhesi
- School of Geography, Earth and Environmental Sciences, The University of Birmingham, Birmingham, UK
| |
Collapse
|
31
|
Chitcharoen S, Sivapornnukul P, Payungporn S. Revolutionized virome research using systems microbiology approaches. Exp Biol Med (Maywood) 2022; 247:1135-1147. [PMID: 35723062 PMCID: PMC9335507 DOI: 10.1177/15353702221102895] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Currently, both pathogenic and commensal viruses are continuously being discovered and acknowledged as ubiquitous components of microbial communities. The advancements of systems microbiological approaches have changed the face of virome research. Here, we focus on viral metagenomic approach to study virus community and their interactions with other microbial members as well as their hosts. This review also summarizes challenges, limitations, and benefits of the current virome approaches. Potentially, the studies of virome can be further applied in various biological and clinical fields.
Collapse
Affiliation(s)
- Suwalak Chitcharoen
- Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand,Research Unit of Systems Microbiology, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
| | - Pavaret Sivapornnukul
- Research Unit of Systems Microbiology, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand,Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
| | - Sunchai Payungporn
- Research Unit of Systems Microbiology, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand,Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand,Sunchai Payungporn.
| |
Collapse
|
32
|
Zheng Y, Liu L, Shi V, Huang W, Liao J. A Resilience Analysis of a Medical Mask Supply Chain during the COVID-19 Pandemic: A Simulation Modeling Approach. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:8045. [PMID: 35805704 PMCID: PMC9265473 DOI: 10.3390/ijerph19138045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 06/27/2022] [Accepted: 06/27/2022] [Indexed: 02/01/2023]
Abstract
The COVID-19 pandemic has caused severe consequences such as long-term disruptions and ripple effects on regional and global supply chains. In this paper, firstly, we design simulation models using AnyLogistix to investigate and predict the pandemic's short-term and long-term disruptions on a medical mask supply chain. Then, the Green Field Analysis experiments are used to locate the backup facilities and optimize their inventory levels. Finally, risk analysis experiments are carried out to verify the resilience of the redesigned mask supply chain. Our major research findings include the following. First, when the pandemic spreads to the downstream of the supply chain, the duration of the downstream facilities disruption plays a critical role in the supply chain operation and performance. Second, adding backup facilities and optimizing their inventory levels are effective in responding to the pandemic. Overall, this paper provides insights for predicting the impacts of the pandemic on the medical mask supply chain. The results of this study can be used to redesign a medical mask supply chain to be more resilient and flexible.
Collapse
Affiliation(s)
- Yi Zheng
- School of Management, Xihua University, Chengdu 610039, China; (Y.Z.); (W.H.); (J.L.)
- China Tourism Academy, Beijing 100005, China
| | - Li Liu
- Research Institute of International Economics and Management Science, Xihua University, Chengdu 610039, China;
| | - Victor Shi
- Lazaridis School of Business and Economics, Wilfrid Laurier University, Waterloo, ON N2L 3C5, Canada
| | - Wenxing Huang
- School of Management, Xihua University, Chengdu 610039, China; (Y.Z.); (W.H.); (J.L.)
| | - Jianxiu Liao
- School of Management, Xihua University, Chengdu 610039, China; (Y.Z.); (W.H.); (J.L.)
| |
Collapse
|
33
|
Wit LA, Fisher B, Naidoo R, Ricketts TH. Economic incentives for the wildlife trade and costs of epidemics compared across individual, national, and global scales. CONSERVATION SCIENCE AND PRACTICE 2022. [DOI: 10.1111/csp2.12735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Affiliation(s)
- Luz A. Wit
- Gund Institute for Environment University of Vermont Burlington Vermont USA
- Bat Conservation International Austin Texas USA
| | - Brendan Fisher
- Gund Institute for Environment University of Vermont Burlington Vermont USA
- Environmental Program Rubenstein School of Environment and Natural Resources Burlington Vermont USA
| | - Robin Naidoo
- Gund Institute for Environment University of Vermont Burlington Vermont USA
- World Wildlife Fund Washington, DC USA
- Institute for Resources Environment and Sustainability, University of British Columbia Vancouver British Columbia Canada
| | - Taylor H. Ricketts
- Gund Institute for Environment University of Vermont Burlington Vermont USA
- Rubenstein School of Environment and Natural Resources University of Vermont Burlington Vermont USA
| |
Collapse
|
34
|
The Role of Public Health Emergency Management in Biodefense: A COVID-19 Case Study. Disaster Med Public Health Prep 2022; 17:e185. [PMID: 35492020 PMCID: PMC9253437 DOI: 10.1017/dmp.2022.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION The emergence of the COVID-19 pandemic has had significant impact on human lives as well as economic and social stability. The United States has a complicated history with biosecurity as policy making, biodefense activities, and government transparency have historically been in contention. The terror attacks of September 11, 2001 uncovered various weaknesses in the national public health infrastructure that have persisted into the current pandemic. METHODS This study explores the biodefense and public health preparedness landscape for trends in federal support and capacity building. It also investigates the applicability of public health emergency management principles to the biodefense structure. A mixed method was utilized in this study to investigate the qualitative and quantitative factors of the research inquiry. Braun and Clarke's six phase framework for thematic analysis will assist with defining the important information from a review of the literature. The concurrent triangulation design permits that use of qualitative and quantitative data to more accurately define and analyze the relationship among the variables of interest. RESULTS The results included the identification of 8 common themes of failure during the COVID-19 response: (1) accountable leadership, (2) statutory authorities and policies, (3) inter-agency coordination, (4) coherent data system for situational awareness, (5) strategic national stockpile and supply chain, (6) testing and surveillance, (7) health care system surge capacity and resilience, and (8) federal funds and the role of public health emergency management in the evolving landscape of biothreats, both intentional and natural. DISCUSSION To counter the increasing biothreats, the United States must invest in revamping the biodefense infrastructure to mimic and support public health emergency preparedness initiatives which will increase our resilience to various biothreats.
Collapse
|
35
|
Fasominu O, Okunromade O, Oyebanji O, Lee CT, Atanda A, Mamadu I, Okudo I, Okereke E, Ilori E, Ihekweazu C. Reviewing Health Security Capacities in Nigeria Using the Updated WHO Joint External Evaluation and WHO Benchmarks Tool: Experience from a Country-Led Self-Assessment Exercise. Health Secur 2022; 20:74-86. [PMID: 35020486 PMCID: PMC8892965 DOI: 10.1089/hs.2021.0095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 09/17/2021] [Accepted: 10/04/2021] [Indexed: 11/13/2022] Open
Abstract
Across the world, the level of pandemic preparedness varies and no country is fully prepared to respond to all public health events. The International Health Regulations 2005 require state parties to develop core capacities to prevent, detect, and respond to public health events of international concern. In addition to annual self-assessment, these capacities are peer reviewed once every 5 years through the voluntary Joint External Evaluation (JEE). In this article, we share Nigeria's experience of conducting a country-led midterm self-assessment using a slightly modified application of the second edition of the World Health Organization (WHO) JEE and the new WHO benchmarks tool. Despite more stringent scoring criteria in the revised JEE tool, average scoring showed modest capacity improvements in 2019 compared with 2017. Of the 19 technical areas assessed, 11 improved, 5 did not change, and 3 had lower scores. No technical area attained the highest-level scoring of 5. Understanding the level of, and gaps in, pandemic preparedness enables state parties to develop plans to improve health security; the outcome of the assessment included the development of a 12-month operational plan. Countries need to intentionally invest in preparedness by using existing frameworks (eg, JEE) to better understand the status of their preparedness. This will ensure ownership of developed plans with shared responsibilities by all key stakeholders across all levels of government.
Collapse
Affiliation(s)
- Olukayode Fasominu
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Oyeladun Okunromade
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Oyeronke Oyebanji
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Christopher T. Lee
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Adejare Atanda
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Ibrahim Mamadu
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Ifeanyi Okudo
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Ebere Okereke
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Elsie Ilori
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| | - Chikwe Ihekweazu
- Olukayode Fasominu, MD, MPH, is a National Consultant, Surveillance; Oyeladun Okunromade, MBBS, MPH, is Deputy Director, Surveillance; Oyeronke Oyebanji, MSc, is a Technical Assistant, Office of the Director General; Elsie Ilori is Director, Surveillance; and Chikwe Ihekweazu, MBBS, FFPH, is Director General; all at the Nigeria Centre for Disease Control, Abuja, Nigeria. Olukayode Fasominu is also Principal, Volte Health Systems Limited, Abuja, Nigeria. Christopher T. Lee, MD, MSc, MPH, is Director, Global Epidemic Preparedness and Response, Resolve to Save Lives, New York, NY. Adejare (Jay) Atanda, DDS, MPH, is a Postdoctoral Fellow, School of Community Health and Policy, Morgan State University, Baltimore, MD. Ibrahim Mamadu, MD, MPH, is a National Programme Officer and Ifeanyi Okudo, MBBS, MPH, is Emergencies Cluster Lead; both in Health Emergency Preparedness and International Health Regulations, World Health Organization Nigeria Country Office, Abuja, Nigeria. Ebere Okereke, MBBS, MSc(PH), FFPHM, is Lead, Public Health England International Health Regulation (IHR) Strengthening Programme, International Health Regulations Strengthening Project, Public Health England, London, UK
| |
Collapse
|
36
|
Hashempour R, Mirhashemi S, Mostafavi H, Mollajafari F, Ahmad Z. Direct medical cost and cost analysis of COVID-19 in Iran: A multicenter cross-sectional study. Int J Crit Illn Inj Sci 2022; 12:10-16. [PMID: 35433401 PMCID: PMC9008290 DOI: 10.4103/ijciis.ijciis_57_21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 08/01/2021] [Accepted: 08/14/2021] [Indexed: 11/04/2022] Open
Abstract
Background: Although our daily life and economics were severely affected by COVID-19, cost analysis of the disease has not been conducted in Iran. Hence, we aimed to perform a cost analysis study and then estimate direct medical costs of COVID-19. Methods: A cross-sectional study was performed in Tehran and recorded medical files from March 1, 2020, to September 1, 2020, were examined. A predefined electronic form was developed and all required variables were included. All people whose both first and final diagnoses were COVID-19 positive and were admitted in governmental hospitals were considered for inclusion. Using stratified random sampling method, 400 medical records were evaluated to gather all data. STATA 14 was used for data analysis. Results: We evaluated 400 medical records and the age of patients ranged from 22 to 71 years. The mean cost of COVID-19 was 1434 USD. Of 400 patients, 129 of them had underlying disease and statistical significance was observed in people who had underlying diseases than people who did not have underlying disease. Conclusion: Beds and medications were the most important factors that added to the costs. COVID-19 has undoubtedly imposed a high financial burden on the health system. It is highly recommended that patients with positive test result be strictly encouraged to stay at home and adhere to safety protocols.
Collapse
|
37
|
Benavides JA, Caparrós C, da Silva RM, Lembo T, Tem Dia P, Hampson K, Dos Santos F. The Power of Music to Prevent and Control Emerging Infectious Diseases. Front Med (Lausanne) 2021; 8:756152. [PMID: 34901067 PMCID: PMC8655130 DOI: 10.3389/fmed.2021.756152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 10/28/2021] [Indexed: 11/19/2022] Open
Abstract
Music is a powerful approach to engage communities and disseminate information. Specifically, health campaigns employing music have been used to promote behaviors that can prevent emerging infectious diseases (EIDs). For example, hip hop artists supported campaigns to prevent acquired immunodeficiency syndrome in the 70s in the United States, while Brazilian funk promoted vaccination to mitigate the ongoing COVID-19 pandemic. Similarly, we broadcast musical messages in local languages to increase community awareness and support prevention measures in Guinea and Liberia in response to the recent Ebola outbreak in 2021. Given the potential of music to promote both individual and population-level behavioral changes to prevent transmission, there is a need to consolidate information on music-based health interventions, and on how we can measure their effectiveness. In this perspective, we provide examples of relevant initiatives, discussing challenges and solutions associated with implementing interventions based on our experience with the 2021 Ebola outbreak. We recommend four steps for a successful music-based health intervention including (1) establishing a task force, (2) compose a "catchy" song including critical preventive measures, (3) deliver the song to the target audience, and (4) evaluate the campaign effectiveness. We argue that close interactions between scientists and musicians can produce rapid musical content for disease prevention. We also identify and discuss several methodological frameworks for testing the effectiveness of such interventions. We conclude that support from public health authorities, government media departments, and international agencies, is necessary to deliver wide outreach and long-term sustainability of musical messaging toward effective EID prevention.
Collapse
Affiliation(s)
- Julio A Benavides
- Departamento de Ecología y Biodiversidad, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile
- Centro de Investigación para la Sustentabilidad, Facultad de Ciencias de la Vida, Centro de Investigación Para la Sustentabilidad, Universidad Andrés Bello, Santiago, Chile
- Department of Veterinary Hygiene and Public Health, São Paulo State University, Botucatu, Brazil
- Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Cristina Caparrós
- Departamento de Ecología y Biodiversidad, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile
- Centro de Investigación para la Sustentabilidad, Facultad de Ciencias de la Vida, Centro de Investigación Para la Sustentabilidad, Universidad Andrés Bello, Santiago, Chile
| | - Ramiro Monã da Silva
- Department of Veterinary Hygiene and Public Health, São Paulo State University, Botucatu, Brazil
| | - Tiziana Lembo
- Boyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | | | - Katie Hampson
- Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Boyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | | |
Collapse
|
38
|
Paul SK, Chowdhury P, Moktadir MA, Lau KH. Supply chain recovery challenges in the wake of COVID-19 pandemic. JOURNAL OF BUSINESS RESEARCH 2021; 136:316-329. [PMID: 34538979 PMCID: PMC8437773 DOI: 10.1016/j.jbusres.2021.07.056] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 07/16/2021] [Accepted: 07/21/2021] [Indexed: 05/06/2023]
Abstract
The COVID-19 pandemic has revealed the fragility of global supply chains arising from raw material scarcity, production and transportation disruption, and social distancing. Firms need to carefully anticipate the difficulties during recovery and formulate appropriate strategies to ensure the survival of their businesses and supply chains. To enhance awareness of the issues, this research aims to identify and model recovery challenges in the context of the Bangladeshi ready-made garment industry. A Delphi-based grey decision-making trial and evaluation laboratory (DEMATEL) methodology was used to analyze the data. While the Delphi method helped identify the major supply chain recovery challenges from the impacts of the COVID-19 pandemic, the grey DEMATEL approach helped categorize the causal relationships among these challenges. Of the 23 recovery challenges finalized, 12 are causal challenges. The study's findings can assist decision-makers in developing strategic policies to overcome the recovery challenges in the post-COVID-19 era.
Collapse
Affiliation(s)
- Sanjoy Kumar Paul
- UTS Business School, University of Technology Sydney, Sydney, Australia
| | - Priyabrata Chowdhury
- School of Accounting, Information Systems and Supply Chain, RMIT University, Melbourne, Australia
| | - Md Abdul Moktadir
- Institute of Leather Engineering and Technology, University of Dhaka, Dhaka 1209, Bangladesh
| | - Kwok Hung Lau
- School of Accounting, Information Systems and Supply Chain, RMIT University, Melbourne, Australia
| |
Collapse
|
39
|
Jedwab R, Khan AM, Russ J, Zaveri ED. Epidemics, pandemics, and social conflict: Lessons from the past and possible scenarios for COVID-19. WORLD DEVELOPMENT 2021; 147:105629. [PMID: 34866756 PMCID: PMC8633882 DOI: 10.1016/j.worlddev.2021.105629] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 07/05/2021] [Indexed: 06/02/2023]
Abstract
Since COVID-19 broke out, there has been renewed interest in understanding the economic and social dynamics of historical and more recent epidemics and pandemics, from the plagues of Antiquity to modern-day outbreaks like Ebola. These events can have significant impacts on the interplay between poverty and social cohesion, i.e. how different groups in society interact and cooperate to survive and prosper. To that effect, this paper provides a theory-driven overview of how social responses to past epidemics and pandemics were determined by the epidemiological and non-epidemiological characteristics of these outbreaks, with a particular focus on the conditions giving rise to scapegoating and persecution of minority groups, including migrants. We discuss existing theories as well as historical and quantitative studies, and highlight the cases where epidemics and pandemics may lead to milder or more severe forms of scapegoating. Finally, we conclude with a summary of priorities for future research on epidemics, pandemics and social conflict and discuss the possible effects and policy implications of COVID-19.
Collapse
Affiliation(s)
- Remi Jedwab
- George Washington University, Elliott School of International Affairs, 603 North Henry St, Alexandria, VA 22314, USA
| | - Amjad M Khan
- George Washington University, Elliott School of International Affairs, 603 North Henry St, Alexandria, VA 22314, USA
| | - Jason Russ
- George Washington University, Elliott School of International Affairs, 603 North Henry St, Alexandria, VA 22314, USA
| | - Esha D Zaveri
- George Washington University, Elliott School of International Affairs, 603 North Henry St, Alexandria, VA 22314, USA
| |
Collapse
|
40
|
Obeng-Kusi M, Habila MA, Roe DJ, Erstad B, Abraham I. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. J Med Econ 2021; 24:1-13. [PMID: 34866541 DOI: 10.1080/13696998.2021.2002092] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
BACKGROUND With the increasing occurrence of infectious diseases in lower-and-middle-income countries (LMICs), emergency preparedness is essential for rapid response and mitigation. Economic evaluations of mitigation technologies and strategies have been recommended for inclusion in emergency preparedness plans. We aimed to perform an economic evaluation using dynamic transition modeling of ebola virus disease (EVD) vaccination in a hypothetical community of 1,000 persons in the Democratic Republic of Congo (DRC). METHOD Using a modified SEIR (Susceptible, Exposed, Infectious, Recovered, with Death added [SEIR-D]) model that accounted for death and epidemiological data from an EVD outbreak in the DRC, we modeled the transmission of EVD in a hypothetical population of 1,000. With our model, we estimated the cost-effectiveness of an EVD vaccine and an EVD vaccination intervention. RESULTS The results showed vaccinating 50% of the population at risk prevented 670 cases, 538 deaths, and 22,022 disability-adjusted life years (DALYs). The vaccine was found to be cost-effective with an incremental cost-effectiveness ratio (ICER) of $95.63 per DALY averted. We also determined the minimum required vaccination coverage for cost-effectiveness to be 40%. Sensitivity analysis showed our model to be fairly robust, assuring relatively consistent results even with variations in such input parameters as cost of screening, as well as transmission, infection, incubation, and case fatality rates. CONCLUSION EVD vaccination in our hypothetical population was found to be cost-effective from the payer perspective. Our model presents an efficient and reliable approach for conducting economic evaluations of infectious disease interventions as part of an emergency preparedness plan.
Collapse
Affiliation(s)
- Mavis Obeng-Kusi
- Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA
| | - Magdiel A Habila
- Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA
- Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
| | - Denise J Roe
- Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
| | - Brian Erstad
- Pharmacy Practice and Science, University of Arizona, Tucson, AZ, USA
| | - Ivo Abraham
- Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA
| |
Collapse
|
41
|
Laban-Sharman A, Majumdar A. Self-Care practices for anxiety during the COVID-19 pandemic in the UK in adults. Ment Health (Lond) 2021. [DOI: 10.32437/mhgcj.v4i1.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
Introduction. The National Health Service cannot chronically sustain the overwhelming demands being placed on it due to financial cuts, staff numbers and presence of Covid-19. As a result, anxiety levels are on the rise thus increasing the need for effective self-care behaviors.Purpose: The purpose of this study was to comprehend and acknowledge the profound influence Covid-19 has had on anxiety levels and explore what behaviors people engage in to manage their perceived stress levels themselves.Methodology: This study was an exploratory mixed-methods design consisting of 110 self-referred adults aged 18-65 with anxiety completed an online survey guided by the “Harvard Anxiety and Depression Scale”. Data collected from the free-text questions were analyzed using the thematic analyses method to evoke the most relevant themes and generate an evidence-based narrative.Results and Discussion: Self-care behaviors used for anxiety self-management pre and during lockdown were walks, virtual family/social peer support, cooking and aerobic exercise. Additionally, it was apparent that a lack of ongoing family/social support was a key predictor for the proclivity of anxiety-inducing thoughts to be experienced. Interestingly, individuals who continually engaged in activity experienced positive mood states irrespective of the current lockdown environment.Conclusion: This study adds to novel literature on the current anxiety levels of adults living in the UK under the Covid-19 pandemic and what self-care behaviors people implement to self-manage their anxiety levels. This study stresses the significance of ongoing peer support as a self-care behavior that can act as a positive meditator for healthy cognitive processes to ensue. Therefore, future self-care programs advocating this strategy may, if not prevent, slow down the rising cases of anxiety and ill mental health due to the uncertain environment of Covid-19
Collapse
|
42
|
Rao GK, Gowthami B, Naveen NR, Samudrala PK. An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. CURRENT RESEARCH IN PHARMACOLOGY AND DRUG DISCOVERY 2021; 2:100063. [PMID: 34870158 PMCID: PMC8498785 DOI: 10.1016/j.crphar.2021.100063] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 10/04/2021] [Accepted: 10/06/2021] [Indexed: 01/08/2023] Open
Abstract
The outbreak of COVID-19 was recognized in December 2019 in China and as of October5th, the pandemic was swept through 216 countries and infected around 34,824,108 individuals, thus posing an unprecedented threat to world's health and economy. Several researchers reported that, a significant mutation in membrane proteins and receptor binding sites of preceding severe acute respiratory syndrome coronavirus (SARS-CoV) to turned as novel SARS-CoV-2 virus and disease was named as COVID-19 (Coronavirus disease 2019). Unfortunately, there is no specific treatment available for COVID-19 patients. The lessons learned from the past management of SARS-CoV and other pandemics, have provided some insights to treat COVID-19. Currently, therapies like anti-viral treatment, immunomodulatory agents, plasma transfusion and supportive intervention etc., are using to treat the COVID-19. Few of these were proven to provide significant therapeutic benefits in treating the COVID-19, however no drug is approved by the regulatory agencies. As the fatality rate is high in patients with comorbid conditions, we have also enlightened the current in-line treatment therapies and specific treatment strategies in comorbid conditions to combat the emergence of COVID-19. In addition, pharmaceutical, biological companies and research institutions across the globe have begun to develop thesafe and effective vaccine for COVID-19. Globally around 170 teams of researchers are racing to develop the COVID-19 vaccine and here we have discussed about their current status of development. Furthermore, recent patents filed in association with COVID-19 was elaborated. This can help many individuals, researchers or health workers, in applying these principles for diagnosis/prevention/management/treatment of the current pandemic.
Collapse
Affiliation(s)
- G.S.N. Koteswara Rao
- College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh 522502, India
| | - Buduru Gowthami
- Department of Pharmaceutics, Annamacharya College of Pharmacy, New Boyanapalli, Rajampet, Andhra Pradesh 516126, India
| | - N. Raghavendra Naveen
- Department of Pharmaceutics, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B.G.Nagar, Karnataka, 571448, India
| | - Pavan Kumar Samudrala
- Department of Pharmacology, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram, 534202, Andhra Pradesh, India
| |
Collapse
|
43
|
Ma Y, Zhang Y, Zhu L. Role of neutrophils in acute viral infection. IMMUNITY INFLAMMATION AND DISEASE 2021; 9:1186-1196. [PMID: 34472718 PMCID: PMC8589350 DOI: 10.1002/iid3.500] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 06/23/2021] [Accepted: 07/22/2021] [Indexed: 12/13/2022]
Abstract
Neutrophils play multiple roles in acute viral infections. They restrict viral replication and diffusion through phagocytosis, degranulation, respiratory burst, secretion of cytokines, and the release of neutrophil extracellular traps, as well as, activate the adaptive immune response. However, the overactivation of neutrophils may cause tissue damage and lead to poor outcomes. Additionally, some characteristics and functions of neutrophils, such as cell number, lifespan, and antiviral capability, can be influenced while eliminating viruses. This review provides a general description of the protective and pathological roles of neutrophils in acute viral infection.
Collapse
Affiliation(s)
- Yuan Ma
- Institute of Infectious Diseases, Peking University Ditan Teaching Hospital, Beijing, China
| | - Yue Zhang
- Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| | - Liuluan Zhu
- Institute of Infectious Diseases, Peking University Ditan Teaching Hospital, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
44
|
Ismail Z, Aborode AT, Oyeyemi AA, Khan H, Hasan MM, Saha A, Akah B. Impact of COVID-19 pandemic on viral hepatitis in Africa: Challenges and way forward. Int J Health Plann Manage 2021; 37:547-552. [PMID: 34462959 PMCID: PMC8653283 DOI: 10.1002/hpm.3317] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2021] [Revised: 08/18/2021] [Accepted: 08/19/2021] [Indexed: 12/22/2022] Open
Abstract
With the overwhelming COVID‐19 pandemic in Africa, many other severe epidemics have been given low priority, such as viral hepatitis. Patient mortality due to viral hepatitis has raised concern to COVID‐19 patients due to compromise with undiagnosed hepatitis in Africa. The pandemic has worsened the control of the viral hepatitis epidemic as healthcare control facilities have moved their focus towards curbing COVID‐19 infections. However, different challenges have arisen to viral hepatitis patients because of low health attention that declines the progress of already diagnosed hepatitis patients. Follow‐up plans, routine testing and treatment plans for viral hepatitis are no longer as strict with the human resources transferred towards combating the pandemic. Thus, a global effort is required to abide by renewed recommendations to eradicate viral hepatitis in Africa that also fit the current picture of the COVID‐19 pandemic. The article discusses the current challenges viral hepatitis patients faced during the COVID‐19 pandemic and important recommendations that can see through these challenges in Africa.
Collapse
Affiliation(s)
- Zainab Ismail
- Faculty of Medicine, Menoufia University, Menoufia, Egypt
| | - Abdullahi Tunde Aborode
- Healthy Africans Platform, Research and Development, Ibadan, Nigeria.,West African Academy of Public Health, Research and Development, Abuja, Nigeria
| | | | | | - Mohammad Mehedi Hasan
- Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.,Division of Infectious Diseases, The Red-Green Research Centre, BICCB, Dhaka, Bangladesh
| | - Anwesha Saha
- Department of Biotechnology, Heritage Institute of Technology, Kolkata, West Bengal, India
| | | |
Collapse
|
45
|
Tirera S, de Thoisy B, Donato D, Bouchier C, Lacoste V, Franc A, Lavergne A. The Influence of Habitat on Viral Diversity in Neotropical Rodent Hosts. Viruses 2021; 13:v13091690. [PMID: 34578272 PMCID: PMC8472065 DOI: 10.3390/v13091690] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 08/15/2021] [Indexed: 12/23/2022] Open
Abstract
Rodents are important reservoirs of numerous viruses, some of which have significant impacts on public health. Ecosystem disturbances and decreased host species richness have been associated with the emergence of zoonotic diseases. In this study, we aimed at (a) characterizing the viral diversity in seven neotropical rodent species living in four types of habitats and (b) exploring how the extent of environmental disturbance influences this diversity. Through a metagenomic approach, we identified 77,767 viral sequences from spleen, kidney, and serum samples. These viral sequences were attributed to 27 viral families known to infect vertebrates, invertebrates, plants, and amoeba. Viral diversities were greater in pristine habitats compared with disturbed ones, and lowest in peri-urban areas. High viral richness was observed in savannah areas. Differences in these diversities were explained by rare viruses that were generally more frequent in pristine forest and savannah habitats. Moreover, changes in the ecology and behavior of rodent hosts, in a given habitat, such as modifications to the diet in disturbed vs. pristine forests, are major determinants of viral composition. Lastly, the phylogenetic relationships of four vertebrate-related viral families (Polyomaviridae, Flaviviridae, Togaviridae, and Phenuiviridae) highlighted the wide diversity of these viral families, and in some cases, a potential risk of transmission to humans. All these findings provide significant insights into the diversity of rodent viruses in Amazonia, and emphasize that habitats and the host’s dietary ecology may drive viral diversity. Linking viral richness and abundance to the ecology of their hosts and their responses to habitat disturbance could be the starting point for a better understanding of viral emergence and for future management of ecosystems.
Collapse
Affiliation(s)
- Sourakhata Tirera
- Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, BP 6010, 97306 Cayenne, France; (S.T.); (B.d.T.); (D.D.); (V.L.)
| | - Benoit de Thoisy
- Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, BP 6010, 97306 Cayenne, France; (S.T.); (B.d.T.); (D.D.); (V.L.)
| | - Damien Donato
- Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, BP 6010, 97306 Cayenne, France; (S.T.); (B.d.T.); (D.D.); (V.L.)
| | | | - Vincent Lacoste
- Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, BP 6010, 97306 Cayenne, France; (S.T.); (B.d.T.); (D.D.); (V.L.)
- Département de Virologie, Institut Pasteur, 75015 Paris, France
- Arbovirus & Emerging Viral Diseases Laboratory, Institut Pasteur du Laos, Vientiane 3560, Laos
| | - Alain Franc
- UMR BIOGECO, INRAE, University Bordeaux, 33612 Cestas, France;
- Pleiade, EPC INRIA-INRAE-CNRS, University Bordeaux, 33405 Talence, France
| | - Anne Lavergne
- Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, BP 6010, 97306 Cayenne, France; (S.T.); (B.d.T.); (D.D.); (V.L.)
- Correspondence:
| |
Collapse
|
46
|
Analysis of Residents’ Preparedness Protocols during Ebola Pandemic in Urban Environment. SUSTAINABILITY 2021. [DOI: 10.3390/su13168934] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background: The study provided empirical analysis of the change in hygiene behavioural practices among community in Ogun and Lagos State with respect to Ebola outbreak in Nigeria. Methods: The data were extracted from a 2015 Cross-Sectional Survey on wellness, knowledge, attitude and practices towards the control and prevention of Ebola virus disease (EVD). Out of 1093 respondents selected in the main survey through simple random sampling technique within two enumeration areas (EAs), only 933 data cases were analyzable, leaving an attrition rate of 14.6%. The EAs represents the sampling points within the local government areas selected for the interviewed. Descriptive and inferential statistical techniques were both employed in the data analysis. Results: The results revealed high level of knowledge of EVD but over 70% were not aware of centre for treatment of EVD; 60.2% believed they cannot be susceptible to EVD. There were changes in certain practices that were canvassed and earlier adhered to during the outbreak. The practice of handshaking reduced, eating of hunted animals decreased only marginally by 6.9% and washing with soap increased by 4%. Conclusion: The study provides helpful insights for public health policy on possible mitigating strategies, especially in terms of behavioral risk factors that are prone to Ebola virus infections or other communicable diseases. The study emphasises that regular hand washing with soap and the use of sanitising agents including availability of treatment centres would be helpful in preventing the occurrence or re-occurrence of pandemic. The protocols identified in this study could be relevant to both medical personnel and the community for adoption especially as the unlikelihood of Ebola (or other pandemic) re-emergence have not been established.
Collapse
|
47
|
Menhat M, Mohd Zaideen IM, Yusuf Y, Salleh NHM, Zamri MA, Jeevan J. The impact of Covid-19 pandemic: A review on maritime sectors in Malaysia. OCEAN & COASTAL MANAGEMENT 2021; 209:105638. [PMID: 33897122 PMCID: PMC8052466 DOI: 10.1016/j.ocecoaman.2021.105638] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 02/26/2021] [Accepted: 03/31/2021] [Indexed: 05/05/2023]
Abstract
The coronavirus disease 2019 or Covid-19 pandemic has affected many operations worldwide. This predicament also owes to the lockdown measures imposed by the affected countries. The total lockdown or partial lockdown devised by countries all over the world meant that most economic activities, be put on hold until the outbreak is contained. The decisions made by authorities of each affected country differs according to various factors, including the country's financial stability. This paper reviews the impact of Covid-19 pandemic on maritime sectors, specifically shipping, fisheries, maritime tourism, and oil and gas sector. The period of this study covers economic activities between the month of January towards the end of July 2020. Also discussed in this journal, is the analysis of the potential post-outbreak situation and the economic stimulus package. This paper serves as a reference for future research on this topic.
Collapse
Affiliation(s)
- Masha Menhat
- Faculty of Maritime Studies, Universiti Malaysia Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia
| | | | - Yahaya Yusuf
- Lancashire Business School, University of Central Lancashire, Preston, Lancashire, PR1 2HE, United Kingdom
| | - Nurul Haqimin Mohd Salleh
- Faculty of Maritime Studies, Universiti Malaysia Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia
| | - Meor Azry Zamri
- UMD Energy Sdn Bhd, The Intermark, 348 Jalan Tun Razak, 50400, Kuala Lumpur, Malaysia
| | - Jagan Jeevan
- Faculty of Maritime Studies, Universiti Malaysia Terengganu, 21030, Kuala Nerus, Terengganu, Malaysia
| |
Collapse
|
48
|
Miethke-Morais A, Cassenote A, Piva H, Tokunaga E, Cobello V, Rodrigues Gonçalves FA, Dos Santos Lobo R, Trindade E, Carneiro D Albuquerque LA, Haddad L. COVID-19-related hospital cost-outcome analysis: The impact of clinical and demographic factors. Braz J Infect Dis 2021; 25:101609. [PMID: 34454894 PMCID: PMC8373618 DOI: 10.1016/j.bjid.2021.101609] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 07/14/2021] [Accepted: 08/08/2021] [Indexed: 01/08/2023] Open
Abstract
INTRODUCTION Although patients' clinical conditions have been shown to be associated with coronavirus disease (COVID-19) severity and outcome, their impact on hospital costs are not known. This economic evaluation of COVID-19 admissions aimed to assess direct and fixed hospital costs and describe their particularities in different clinical and demographic conditions and outcomes in the largest public hospital in Latin America, located in São Paulo, Brazil, where a whole institute was exclusively dedicated to COVID-19 patients in response to the pandemic. METHODS This is a partial economic evaluation performed from the hospital´s perspective and is a prospective, observational cohort study to assess hospitalization costs of suspected and confirmed COVID-19 patients admitted between March 30 and June 30, 2020, to Hospital das Clínicas of the University of São Paulo Medical School (HCFMUSP) and followed until discharge, death, or external transfer. Micro- and macro-costing methodologies were used to describe and analyze the total cost associated with each patient's underlying medical conditions, itinerary and outcomes as well as the cost components of different hospital sectors. RESULTS The average cost of the 3254 admissions (51.7% of which involved intensive care unit stays) was US$12,637.42. The overhead cost was its main component. Sex, age and underlying hypertension (US$14,746.77), diabetes (US$15,002.12), obesity (US$18,941.55), chronic renal failure (US$15,377.84), and rheumatic (US$17,764.61), hematologic (US$15,908.25) and neurologic (US$15,257.95) diseases were associated with higher costs. Age strata >69 years, reverse transcription polymerase chain reaction (RT-PCR)-confirmed COVID-19, comorbidities, use of mechanical ventilation or dialysis, surgery and outcomes remained associated with higher costs. CONCLUSION Knowledge of COVID-19 hospital costs can aid in the development of a comprehensive approach for decision-making and planning for future risk management.
Collapse
Affiliation(s)
- Anna Miethke-Morais
- Clinical Director´s Office, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil
| | - Alex Cassenote
- Department of Gastroenterology, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil; Santa Marcelina Faculty, Discipline of Labour Market and Physician's Health, São Paulo, SP, Brazil; Medical Demography Study Group, Department of Preventive Medicine, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil
| | - Heloisa Piva
- Executive Director´s Office, Instituto Central, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil
| | - Eric Tokunaga
- Strategy and Operations Department, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil
| | - Vilson Cobello
- Information Technology Department, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil
| | - Fabio Augusto Rodrigues Gonçalves
- Health Technology Assessment Center, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil; Central Laboratory Division, Instituto Central, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil
| | - Renata Dos Santos Lobo
- Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil
| | - Evelinda Trindade
- São Paulo State Health Technology Assessment Network, REPATS-SES/SP, São Paulo State Health Secretariat, SP, Brazil; Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil
| | - Luiz Augusto Carneiro D Albuquerque
- Department of Gastroenterology, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil; Gastroenterology Department, Digestive Organs Transplant Division, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil
| | - Luciana Haddad
- Department of Gastroenterology, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil; Gastroenterology Department, Digestive Organs Transplant Division, Faculty of Medicine FMUSP, University of São Paulo, São Paulo, SP, Brazil.
| |
Collapse
|
49
|
Parihar S, Kaur RJ, Singh S. Flashback and lessons learnt from history of pandemics before COVID-19. J Family Med Prim Care 2021; 10:2441-2449. [PMID: 34568118 PMCID: PMC8415662 DOI: 10.4103/jfmpc.jfmpc_2320_20] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 02/16/2021] [Accepted: 03/17/2021] [Indexed: 12/24/2022] Open
Abstract
With an increasing frequency of infectious disease outbreaks, the COVID-19 pandemic causing mortality around the world and the threat of similar future events looming large, mankind is faced with the herculean task of counteracting such threats with the best possible strategies and public health decisions. It is key that such decisions should be guided by previous examples of similar health emergencies. Here we review some of the significant infectious disease outbreaks, including epidemics and pandemics occurring worldwide in the past including their impact at population and global levels, unique challenges presented by each and the measures taken by authorities worldwide as well as the crucial lessons each epidemic or pandemic provided. This review highlights that throughout history measures such as contact tracing, quarantine and isolation have been incredibly effective in limiting an outbreak in its severity, thus ensuring accurate information flow to the public is as essential as limiting the spread of misinformation. With global populations rising, surveillance for emerging and re-emerging pathogens will play an immense role in preventing future epidemics or pandemics. And finally that even though for novel strains or pathogens, although vaccines are thought to be an irreplaceable defense, but their development and distribution in time to curb an epidemic has seldom been witnessed and remains an important challenge for the future. Hence, we conclude that looking at these past examples not only highlights the important knowledge gained for the strategies to devise, but also the mistakes that can be avoided in the way forward.
Collapse
Affiliation(s)
| | | | - Surjit Singh
- Department of Pharmacology, AIIMS, Jodhpur, Rajasthan, India
| |
Collapse
|
50
|
Pirasteh-Anosheh H, Parnian A, Spasiano D, Race M, Ashraf M. Haloculture: A system to mitigate the negative impacts of pandemics on the environment, society and economy, emphasizing COVID-19. ENVIRONMENTAL RESEARCH 2021; 198:111228. [PMID: 33971127 PMCID: PMC8110177 DOI: 10.1016/j.envres.2021.111228] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 04/21/2021] [Accepted: 04/22/2021] [Indexed: 05/03/2023]
Abstract
COVID-19 (coronavirus disease) is a global pandemic that started in China in 2019 and has negatively affected all economic sectors of the world, including agriculture. However, according to estimates in different countries, agriculture has suffered less than other sectors such as construction, industry and tourism, so agricultural development can be a good option to compensate for the economic damage caused to other sectors. The quality of available water and soil resources for agricultural development is not only limited, but is also decreasing incrementally, so the use of saline and unconventional soil and water resources is inevitable. Biosaline agriculture or haloculture is a system in which highly saline water and soil resources are used sustainably for the economic production of agricultural crops. It seems that in the current situation of the world (with COVID-19's impact on agriculture on the one hand and the quantitative and qualitative decline of freshwater and soil on the other), haloculture with a re-reading of territorial capabilities has good potential to provide a part of human food supply. In this review article, the potential of haloculture to offset the adverse impacts of the pandemic is analyzed from five perspectives: increasing the area under cultivation, using unconventional water, stabilizing dust centers, increasing the body's immune resistance, and reducing losses in agribusiness due to the coronavirus. Overall, haloculture is an essential system, which COVID-19 has accelerated in the agricultural sector.
Collapse
Affiliation(s)
- Hadi Pirasteh-Anosheh
- National Salinity Research Center, Agricultural Research, Education and Extension Organization, Yazd, 8917357676, Iran.
| | - Amir Parnian
- National Salinity Research Center, Agricultural Research, Education and Extension Organization, Yazd, 8917357676, Iran
| | - Danilo Spasiano
- Department of Civil, Environmental, Land, Building Engineering and Chemistry, Polytechnic University of Bari, Bari, 70125, Italy
| | - Marco Race
- Department of Civil and Mechanical Engineering, University of Cassino and Southern Lazio, Cassino, 03043, Italy.
| | | |
Collapse
|